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Abstract 
 
 
 
Mycobacterium avium subsp. paratuberculosis (Mpt), the causative agent of 
Johne’s disease (JD), is a global problem in the agricultural industry.  It is estimated that 
25% of all U.S. dairy herds are JD positive.  One obstacle in the management of JD is the 
lack a sensitive diagnostic test for use during the early stages of infection.  Resuscitation 
promoting factors (Rpf) are proteins that promote the growth of many species of 
Actinobacteria.  If Rpf proteins could enhance the growth of Mpt, the sensitivity of 
diagnostic fecal culture could be improved, and the impact of JD on the dairy industry 
would be significantly reduced.  The putative rpf translation products from four open 
reading frames (ORFs) in the genome of Mpt have been designated as Rpf homologues, 
but their function as true Rpf proteins has not been demonstrated.  Bioinformatic and 
sequence alignment analysis supported the previous identification of four ORFs as rpf 
homologues in Mpt, and further indicated that each of these homologues contains motifs 
demonstrated to be critical for Rpf function.  I cloned the Mpt homologue of rpfB in E. 
coli and optimized the conditions necessary for expression.  The recovered expression 
products were tested against dormant Mpt.  Although the recombinant protein exhibited 
effects in E. coli consistent with Rpf expression, dormant Mpt did not respond to 
recombinant RpfB.  This may have been due to the loss of functional conformation 
during the purification process. Further, RpfB alone may not be sufficient to resuscitate 
dormant Mpt. 
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1 
Introduction 
 
 
 
 Animal disease accounts for a significant annual economic loss to the agricultural 
industry.  Farmers must invest in controlling animal disease to ensure a healthy herd, and 
a product of consumable quality.  The farmer’s investment must be returned in order to 
justify the costs accrued.  Those who consume the products will make up the cost of 
investing in the herd.  If the cost of managing animal diseases can be reduced, the market 
price for products from animals will also be reduced.   
 Johne’s disease (JD), caused by Mycobacterium avium subsp. paratuberculosis 
(Mpt), is a chronic wasting disease that is particularly significant in dairy and beef cattle, 
sheep, and goats; however it can also be found among wild ruminants (18).  In 2008, the 
prevalence of JD in dairy herds was estimated to be 25% (101).  The average economic 
cost of JD can be $229/cow/year (81).  Estimates have placed the annual cost of JD to be 
as much as $1.5 billion (90).  Efforts to eradicate Mpt from the agricultural process have 
been unsuccessful.  Current JD management practices have helped decrease the incidence 
of JD.  However, the current diagnostic techniques are insufficient in distinguishing 
uninfected animals from animals in the early stages of infection.  
The course of JD can be broken down into 3 stages.  Stage 1 is classified as early 
infection, most commonly seen in animals less than 2 years of age.  During this period 
the infected animal does not show signs of disease, and Mpt is shed from the infected 
animal at levels below the limits of detection.  The second stage is classified as 
subclinical infection.  Subclinical infection is seen in animals that have been infected for 
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approximately 2-4 years.  The infected host appears to be healthy, but may be a threat to 
surrounding stock due to an increase in the amount of Mpt being shed.  The final stage of 
infection is classified as clinical infection.  During clinical disease, animals progressively 
show signs including emaciation, watery diarrhea, and a decrease in milk production.  
Evidence of Mpt infection is easily accomplished during this stage of disease. 
The organism is spread from animal to animal through the fecal-oral route by way 
of contaminated food and water, nursing from infected dams, or transplacentally (18).  
The infectious dose of Mpt has not been clearly established.  The onset and progression 
of JD can vary depending on the number of organisms ingested, as well as the age of the 
animal (3).  Mpt inocula at concentrations between 108 and 1010 are commonly used to 
experimentally infect animals through ingestion (18).  However, orally administered 
doses of Mpt at concentrations as low as 103 have also successfully produced an infection 
(18).  It is estimated that animals in the clinical stage of infection shed 5x1012 
mycobacteria per day (14).  Currently, the most effective way to control the spread of the 
organism is through hygienic herd management, early detection, and culling of infected 
animals.   
 Early detection of infection is one of the objectives in the successful management 
of JD.  Fecal culture (FC) is the “gold standard” for detecting Mpt.  FC is laborious, 
expensive, has a slow turn around time, and frequently leads to false-negative diagnoses 
due to poor sensitivity during the early stages of JD.  Considering that FC is the gold 
standard used in the diagnosis of JD, the efficiencies of all other diagnostic tests are 
evaluated against FC.  Diagnostic tests that are manipulated to have higher sensitivities 
than FC are considered to give false-positive results, due to the accepted consideration 
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that animals not shedding Mpt do not have JD.  Improving the sensitivity of FC during 
the early and subclinical stages of disease would legitimize the elevated sensitivities of 
other diagnostic methods that are inexpensive and have rapid turn around times, and 
would lead to fewer false-negative diagnoses.   
In order to increase the efficacy of JD diagnostics, work must first be done to 
improve the diagnostic gold standard.  The first thing we must learn about Mpt infections 
is whether or not an infected host in the early stages of disease is always shedding Mpt.  
It is currently held that Mpt-infected hosts intermittently shed Mpt during the early stages 
of disease.  However, infected hosts may always be shedding Mpt, but the accepted 
methods of FC may only support the intermittent detection of Mpt during the early stages 
of disease.  If it is found that Mpt is always being shed from infected animals, it will be 
likely that a fraction of the Mpt is in a non-culturable state.  Although the available 
diagnostic growth media have been optimized for the recovery of culturable Mpt, it is 
poorly understood how viable but not culturable bacteria respond to these media.   
The sensitivity of FC may be affected by the physiological state of Mpt.  It is 
possible that organisms in a physiologically dormant state cannot be successfully cultured 
by standard FC methods.  Dormancy results when conditions for growth are less than 
optimal, possibly similar to those encountered within a granuloma.  Reactivation of 
dormant cells can result in the reactivation of a latent infection, diffusion of an existing 
infection, or cause new infections upon entry into a new host.  Recovery from dormancy 
is dependent on signaling factors produced by actively growing cells.  Isolation of the 
signals that cause the resuscitation of dormant Mpt could be used in concert with FC to 
recover dormant Mpt in vitro.  This would permit the means to determine whether or not 
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dormant Mpt are being shed from infected hosts during the stages of JD where standard 
FC is unreliable.   
Growth factors known as Resuscitation Promoting Factors (Rpf) have been shown 
to promote the growth of related organisms that were previously dormant.  Rpf proteins 
are highly conserved among Actinobacteria.  The Rpf proteins of M. tuberculosis have 
been shown to greatly increase the culturability of previously uncultivable mycobacteria.  
To the writer’s knowledge, only one experiment has been published on the ability of a 
Rpf to stimulate the growth of Mpt in vitro (117).  
 In the annotated genome of Mpt, there are four hypothetical proteins that share 
homology with Rpfs of related bacteria.  If it is determined that Mpt expresses these 
genetic elements, recombinant Rpfs could be produced and incorporated into diagnostic 
culture media to facilitate a more rapid and accurate diagnosis of subclinical animals, and 
possibly improve the detection of Mpt-shedding animals within the early disease stage.   
 Our purpose in this study was to determine if Mpt contained the necessary genetic 
elements for functional Rpf proteins, and if dormant Mpt would respond to those Rpf 
proteins.  We analyzed the Mpt Rpf homologues, and determined that the critical amino 
acids for Rpf function are present.  We cloned the four rpf sequences into a mycobacterial 
expression vector; however we were unable to obtain any expression products from those 
vectors.  We successfully expressed the putative rpfB in E. coli, and saw activity in E. 
coli consistent with that of Rpf proteins.  When the purified RpfB was tested against 
dormant Mpt we did not detect any resuscitative response.   
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Literature Review 
 
 
Mycobacterium avium subsp. paratuberculosis (Mpt) is the causative agent of 
paratuberculosis, or Johne’s disease (JD); a chronic intestinal disease characterized by 
inflammation of the ileum and granulomatous enteritis of domestic and wild ruminants 
(12, 26, 38, 48, 68, 81, 94, 103).  The economic consequences of this disease are 
particularly significant in dairy herds.  In 1997, estimates by The National Animal Health 
Monitoring System (NAHMS) stated that 21.6% of dairy herds were infected (102).  This 
number increased to 25% of dairy herds in 2008 (101).  The economic consequence of JD 
can be as much as $1.5 billion in the dairy industry (38, 90).   
Mycobacterium tuberculosis and M. leprae are the most well-known 
mycobacterial pathogens of humans, collectively infecting nearly 9.5 million new 
individuals each year (37, 82).  Notable mycobacterial animal pathogens include M. 
bovis, M. avium subsp. avium, and Mpt.  The common features of mycobacterial 
infections have led to the consideration of Mpt in the pathogenesis of Crohn’s disease (8, 
9, 12, 13, 36, 59, 68, 80, 105); however, this remains controversial.       
Mpt has the slowest generation time of all cultivable mycobacteria, at 
approximately 20 hours (50).  The genomic comparison of Mpt to M. tuberculosis 
indicates that this slow growth may have resulted from an insertion near oriC, as well as 
numerous nucleotide substitutions in genes encoding enzymes for purine synthesis (78).  
The most notable phenotypic difference between Mpt and other mycobacteria is the in 
vitro dependence of the former on mycobactin J, a siderophore.  It is thought that this 
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dependency may be due to the truncation of the mbtA gene (53).  The reliance on an 
intermediate iron supplier secures the obligate parasitism of Mpt.  
 
Infection and Immunity 
Infection begins with the consumption of milk or feed contaminated with Mpt.  
While moving through the small intestine, Mpt comes into contact with mucosa-
associated lymphoid tissue where it crosses through M cells of the ileal Peyer’s patches 
(38, 60).  M cells are a common portal of entry for pathogens due to reduced levels of 
brush-border microvilli, digestive enzymes, and surface mucus at this site (32).  Mpt then 
passes from ileal M cells to subepithelial and intraepithelial macrophages (60).  
Following endocytosis by macrophages of the Peyer’s patches, the fate of Mpt depends 
on the maturation of the phagosome.  If maturation occurs, the chances of Mpt surviving 
are greatly diminished.  Maturation occurs in approximately 30% of phagocytic cases 
(115), and can lead to successful antigen presentation to reactive T-cell populations (26).  
If maturation of the phagosome does not occur, the environment Mpt encounters is less 
acidic and less toxic than in the case of normal phagosome trafficking.   
The importance of phagosome trafficking extends to the reliance of Mpt on an 
intermediate iron supplier.  The means by which Mpt obtains iron in vivo has eluded 
scientists to date.  Brooks et al. characterized a 40 kDa protein called antigen D, the 
sequence of which resembles E. coli bacterioferritin (7). The role antigen D plays in iron 
acquisition for Mpt has yet to be confirmed.  Lambrecht and Collins determined that 
mycobacteria are unable to access iron bound to siderophores of unrelated organisms; 
however, at a pH between 5-6.2, iron dissociation from host siderophores – transferrin 
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and lactoferrin – will promote the growth of Mpt without mycobactin (51).  The pH 
inside of a Mpt phagosome is 6.2-6.3 (43).  In addition to this, Mpt-containing 
phagosomes have increased levels of transferrin receptors (TFR), which are responsible 
for transporting transferrin into early-stage endosomes (44).  Mpt also produces an 
extracellular ferric reductase that could play a role in Fe2+ acquisition from chelated Fe3+ 
(42).  Due to Mpt’s lack of SOD activity, this reductase would also offer protection by 
making Fe3+ unavailable to H2O2-producing enzymes (42).  In addition, the increased 
levels of TFR on Mpt-containing phagosomes suggest that Mpt may gain access to iron 
from transferrin (43, 44).   
The complexity of immune responses during this multistage disease cannot be 
summed up in the simple paradigm of a Th1-Th2 shift (27).  A synthesis of literature 
from reports describing immune responses to Mpt infection can be confusing because of 
variables such as methods and location of experimental inoculation, murine vs. ruminant 
hosts, location of sampling for cytokine detection, identification and quantitation of 
cytokines via mRNA transcripts vs. direct cytokine screening, and determining which 
disease stage (if any) is being examined.  A number of workers have reviewed the 
available literature with regard to disease progression and host responses to Mpt infection 
(26, 88, 91). Conclusions from these reports weighed the determinants of infection on a 
controlled Th-type 1 response.  If stabilized by the host, there is little likelihood that the 
infection will progress to the subclinical stage, and protective immunity can result from 
circulating Mpt-reactive CD8+ T lymphocytes (95).   
The first response to the presence of Mpt is the production of the proinflammatory 
cytokines interleukin (IL) 1α, IL-6, and gamma interferon (IFN-γ) as well as upregulation 
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of tumor necrosis factor associated receptor factor 1 (TRAF1) (26).  Through IL-2/CD25 
signaling, Th-1 and suppressor T-cell populations begin proliferation and production of 
IL-10, respectively (26).  
Signs of IL-1α toxicity characterize the progression of infection into the sub-
clinical phase.  Lack of a TNF-α response sufficient to result in the formation of 
granulomas leads to the dissemination of infection (26).  Granulomas of tuberculosis 
have been characterized as avascular structures consisting of 3 basic layers.  The first is 
the outermost layer, composed of resting macrophages and lymphocytes.  The second 
layer is composed of activated macrophages.  The third layer is the caseous center, 
composed of viable bacteria, bacterial fragments, and killed macrophages (43).   
The enhanced survival of infected macrophages may also be the result of high 
levels of TRAF1 surface expression, which prevent these cells from undergoing 
apoptosis.  Mpt causes further recruitment of macrophages, and selection for and 
containment of suppressive T-cell populations by maintaining steady host production of 
IL-1α, IL-8, IL-10, and augmentation of the population shift from Th-1 to cytotoxic 
suppressor cells (26).  Interestingly, a tie is yet to be made between the abundance of IL-8 
and the lack of neutrophil infiltration.   
Once the host has progressed to the clinical stage of disease, the active cell 
population has shifted almost exclusively to the response of macrophages, cytotoxic 
suppressor cells, and B cells.  This combination marks total loss of control and regulation 
over the infection, and Mpt moves about the host unchecked.  The resulting pathogenesis 
leads to extensive inflammation and damage to the ileum, granuloma formation, and 
thickening of the lumen intestinal wall (38).  The distortion of villous absorptive tissue 
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lining the intestine leads to the subsequent development of malabsorptive diarrhea, 
wasting of the infected animal, and death.  The explosive diarrhea that occurs during the 
clinical stage results in the shedding of large numbers of infectious Mpt which can be 
readily ingested by the surrounding stock; including those at highest risk of infection – 
neonatal and juvenile calves (38, 81).   
Although calves become infected with Mpt, Mpt cannot be reliably recovered in 
culture during the early stage of disease.  After this stage, calves may or may not progress 
to the subclinical stage (71).  This puts a high demand on the development of new 
technologies that aid the early diagnosis by the identification of Mpt-infected animals. 
 
Diagnosis 
Fecal culture is considered to be the gold standard in detecting Mpt infection due 
to its near absolute specificity and high analytical sensitivity in detecting animals with 
clinical infection.  However, fecal culture is very time consuming, taking up to 16 weeks 
to complete (81).  Modifications to classical fecal culture techniques have significantly 
reduced the detection time for cattle with clinical infections (81).  In contrast to clinical 
infection, detection of infection in asymptomatic animals is still problematic, both in 
terms of time and sensitivity: the sensitivity of fecal culture relative to infection is 
estimated to be between 30% and 50% (17, 57). 
Enzyme linked immunosorbent assay (ELISA) is another method frequently used 
in diagnosis.  Although the specificities of ELISA kits are routinely high, the specificities 
can vary.  This can result from the quality of the Mpt antigen used in the ELISA, and 
whether the antibody shares cross-reactivity with other environmental mycobacteria (23, 
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24).  The sensitivity of ELISAs vary with the age of the animal being tested (66), as well 
as the disease state of the host.  The sensitivity of serological diagnostic methods 
increases with the progression of disease.  ELISA testing has great utility for rapid 
diagnosis and guiding proper management practices, but does not provide us with a 
sensitivity equal to that of diagnostic culture tests (24).  When the infection is controlled 
by the cell-mediated response, indirect ELISA has a very low sensitivity.  As the animal 
ages and the infection progresses, the humoral response becomes active and the 
sensitivity increases with the production of antibodies; however, by the time antibody 
levels become detectable, the infection has likely progressed to a terminal stage (26).  
This makes ELISA suitable to examine the infectiousness of an animal, but not as a 
determinant of infection in early diagnosis (66).   
Success has been made in modifying these tests to improve their sensitivity and 
specificity; however when their diagnostic efficiency is examined, it is always compared 
against fecal culture.  Other methods for detecting Mpt infections include brightfield-
microscopic examination of acid-fast smears, fluorescence in situ hybridization, 
complement fixation, agarose gel immunodiffusion, the gamma interferon assay, and 
IS900 DNA detection.  These methods have not been widely accepted due to their 
inability to distinguish among previous exposure, disease latency, and active infection, as 
well as the test probes lacking necessary sensitivity and/or specificity (81).   
 
Persistence and Dormancy 
Despite their apparent simplicity, prokaryotes are highly adaptive organisms that 
have the ability to sustain themselves under a variety of environmental conditions (93).  
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Survival of parasitic organisms within ecological habitats can pose a selective advantage 
for them by means of transfer within biological vectors.  Both Mpt and the closely related 
Mycobacterium avium subsp. avium have been shown to survive and replicate within a 
number of protozoa following both phagocytosis and encystment (78, 92, 111).  This 
capability affords them a greater resistance to antimicrobial drugs and chemical 
disinfection (58, 111), the ability to disperse through aerosolization of Mpt-infected cysts 
(78), and concurrent infection through entrance of the intestinal epithelium within 
pathogenic amoeba (16).   Insects and nematodes have also been implicated as possible 
biological vectors for the transfer of Mpt.  Insects and insect larvae feed on the feces of 
Mpt infected cattle and intestinal matter in slaughterhouses (34), and can be consumed by 
potential hosts along with grasses and feed.  Parasitic nematodes could possibly enhance 
the virulence of Mpt by reducing the infectious dose required for infection (6, 112).  
Whittington et al. has shown the Mpt can survive outside the host for as many as 55 
weeks in the soil, and 65 weeks in distilled water (113). 
It has long been held that animals in the early and sub-clinical stages of disease 
shed Mpt in feces intermittently, which would explain the poor sensitivity of fecal culture 
in these stages.  However, it is possible that infected animals may always be shedding 
Mpt, but those being shed by animals in the early stages of disease – when the host is 
able to suppress replication – are not able to withstand growth on the rich, selective 
media used for primary culture due to oxidative damage from increased metabolism.  
In some non-spore forming bacteria, growth-limiting conditions (such as 
restriction of growth in granulomas or environmental restrictions) cause organisms to 
enter a non-culturable state called dormancy, which can last for decades (12, 63, 110).  
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Dormancy has been defined as a reversible phase in which the organism has drastically 
reduced its metabolism and persists without replication (104).  The adoption of this 
inactive state can be the result of suboptimal growth conditions which lead to the 
reduction of metabolic activity, formation of more rigid cellular components, and a shift 
in catabolic pathways (110).  Extended periods of time in a state of non-replicating 
persistence can lead to an organism remaining viable, but not culturable (VBNC) (77).  
 This can also be referred to as non-replicating persistence (NRP). 
A number of models have been tested on the transition of organisms into a state of 
NRP (110).  To better understand the mechanisms of transition, it is important to consider 
the conditions under which an organism is forced to enter NRP.  Pathogenic 
mycobacteria must overcome the obstacle of maintaining viability within granulomas.    
Concerning M. tuberculosis granulomas, the substrate availability in the caseous slurry 
(83, 116) and the necrotic tissue at a pH of approximately 6.5 (110) are conducive for 
ongoing metabolism.  However, over time within a granuloma the decreased oxygen 
availability limits the ability of mycobacterial cells to grow and divide (10, 45, 79, 110).  
Granulomas that result from an Mpt infection can differ from granulomas caused by M. 
tuberculosis.  They typically do not differentiate as well, and caseation only occurs in 
ovine hosts.   
According to the Wayne dormancy model (107), when oxygen supplies diminish 
to approximately 1% of ambient oxygen concentrations, M. tuberculosis begins its decent 
into anaerobic respiration in what they refer to as NRP-1 (107).  The organism halts 
division, thickens its cell wall, replicates its chromosome one final time, and with a 
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continued deprivation of oxygen enters a survival transition into what they refer to as 
NRP-2 (107).   
The use of nitrate reduction and the glyoxylate shunt are both important during 
the transition to NRP.  Nitrate reductase genes are induced in M. tuberculosis during 
hypoxia and exposure to nitric oxide (89).  Reducing nitrate allows this organism to 
generate ATP during periods of anaerobiosis (89, 108, 110).  Although putative genes for 
assimilatory nitrate and nitrite reduction, and nitrate/nitrite transporters have been 
identified in Mpt (2), the effects of such gene products have yet to be tested in Mpt. The 
reductive amination of glyoxylate by way of the glyoxylate shunt promotes the 
conservation of carbon, the preservation of biosynthetic intermediates, and the means to 
regenerate NAD through the activity of glycine dehydrogenase (109).  It has been 
proposed by Wayne and Lin that NAD production from reductive amination of 
glyoxylate would provide the means to generate the ATP required to complete a final 
cycle of DNA replication before the termination of cell division (109).  The sensitivity of 
mycobacteria in the state of NRP, or transition to NRP, to metronidazole may indicate 
that these organisms have the ability to respire anaerobically (107).  However, the 
reductive potential required for the activity of metronidazole may exist in a 
microaerophilic environment (reductive potential below -430 mV) (31, 107).   
Within a granuloma, successful entrance into NRP would require a very gradual 
and organized alteration of metabolic processes.  Through gradual oxygen depletion, in 
vitro experiments have produced non-replicating bacteria that survived for 12 years (25).  
Upon re-introduction into an aerated medium, these non-replicating cells grew and 
divided immediately (107). 
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Successful recovery from a state of NRP depends heavily on the rate of entrance 
into NRP-1 and NRP-2 (107).  Cells that are rapidly depleted of oxygen will not spend 
enough time in NRP-1, and their chances of survival during NRP-2 become greatly 
diminished (106, 109).  Addressing these issues in an in vivo system, Canetti noted that 
conditions would differ greatly per granuloma, with the specific variables affecting 
successful NRP, including cellular composition, the extent of caseation and liquefaction, 
and oxygen availability (110).   
In some cases of extended dormancy, mycobacteria shed their cell walls and enter 
a spheroplastic state (15).  This allows the organism to more efficiently evade 
phagocytosis, and therefore remain undetected in a host for longer periods of time.  
Mycobacterial spheroplasts have been found to exist within a host (15).  These 
spheroplasts are metabolically active, capable of reverting back to their normal cell-
walled form, and infectious upon reversion (15, 73, 100).  Recovery and reversion of 
experimentally induced mycobacterial spheroplasts can vary from as low as 0.1% to as 
high as 20% (15, 100).  Rates of reversion in vivo are currently unknown.  
 
Bacterial Communication 
For many actinomycetes, successful resumption of growth from dormancy is 
dependent on signaling factors produced by the population of cells (61, 63, 64).  When 
gene expression is determined by population density, it is referred to as quorum sensing 
(QS) (96).  QS plays a role in the activation of genes that are beneficial at high bacterial 
load, commonly exemplified by the bioluminescence of Vibrio fischeri following the 
activation of the lux operon of that organism (96, 114).  It has been demonstrated that 
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Gram-positive organisms also use a pheromone-based QS motif (61).  The effects of this 
include competence, virulence, antimicrobial peptide production, and possibly 
resuscitation.   
The classical mechanism of QS in Gram-positive bacteria starts with a post-
translationally modified peptide that gets secreted via an ATP-binding-cassette (ABC) 
exporter.  The signal is received by a transmembrane sensor, which becomes 
phosphorylated.  The phosphorylated component combines with the response regulator to 
act as an inducer molecule for the operon.  The process is autoregulated by having the 
genes that code for the signaling peptide, the ABC exporter, and the two-component 
regulatory system transcriptionally linked (49).  This particular model is specific to 
biological molecules that are produced as a means of direct communication and 
population sampling.   
There is also a means of biochemical signaling by molecules that are not 
produced with the sole intent of communication, but their presence can result in 
phenotypic changes in the organism detecting them.  One example includes muropeptides 
incorporated into the peptidoglycan of bacterial cell walls.  When serving their primary 
purpose, they contribute to the structural integrity of an organism.  When recognized as a 
free-floating entity, they can act as a regulatory stimulus (30, 35, 47, 76). Peptidoglycan 
can act as a signaling molecule by way of serine/threonine protein kinases (STPK) (85).  
While studying the PASTA (penicillin-binding protein and serine/threonine kinase 
associated) domain kinase PrkC, Shah et al. showed that m-DAP- containing 
muropeptides acted as a strong stimulus for the germination of Bacillus endospores (47, 
84).  Mycobacteria express an essential STPK homologue to PrkC called PknB, that is 
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downregulated in response to carbon starvation, and therefore activated during periods of 
growth (4, 33).  The possible significance of PknB in relation to peptidoglycan structure 
will be discussed below.  
 
Resuscitation Promoting Factors 
Micrococcus luteus, a member of Order Actinomycetales (high G+C content 
bacteria), produces an autoinducing proteinaceous growth factor known as resuscitation-
promoting factor (Rpf protein) (12, 38, 61).  It has been shown by Mukamolova and 
colleagues that Rpf proteins are highly conserved and promote growth of many 
Actinobacteria, including several species of mycobacteria (64).  Their importance has 
even extended to infectious mycobacteriophages that conserve them within protein tails 
for the purpose of cell wall penetration, and possible cell-cycle initiation (70). 
Analysis of N-terminal processing has suggested that Rpf proteins could be uniquely 
involved in autocrine and paracrine signaling (61, 64).  
Mukamolova and colleagues have shown that there is cross-species interaction 
among mycobacteria that produce Rpf proteins.  In one such instance, picomolar 
concentrations of the Rpf proteins of M. tuberculosis were able to stimulate a >10-fold 
increase in the population of previously dormant M. bovis within a 60-day incubation 
period, while reducing the time for induction of logarithmic growth to approximately 20 
days (depending on which Rpf was assayed) (64).  Zhu et al. confirmed that Mpt also 
responded to Rpf proteins at picomolar concentrations (117).  Their work showed that 
Mpt could be recovered from a dormant state when recombinant putative Mpt RpfA was 
added to culture media at concentrations between 8 and 128 picomolar.   
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There are five rpf genes in the genome of M. tuberculosis designated rpfA 
(Rv0867c), rpfB (Rv1009), rpfC (Rv1884c), rpfD (Rv2389c), and rpfE (Rv2450c) (28, 
29, 64, 98, 99).  Basic Local Alignment Sequencing Tool (BLAST) (1) searches have 
revealed that each of the genes rpfA, rpfB, rpfC, and rpfE has a homologue within the 
genome of Mpt (47).  If the function of these homologues in Mpt is similar to Rpf 
function in M. tuberculosis, it may be possible to incorporate products of these rpf 
homologues into culture media to improve the sensitivity of diagnostic culture. 
It was initially presumed by Mukamolova et al. that rather than functional 
redundancy, each Rpf might be expected to serve a unique purpose in specific situations 
(61).  Work with mutants harboring null mutations in the rpf sequences has shown that 
rpf mutations do not affect the growth of M. tuberculosis in liquid media (46, 98).  All 
Rpfs are dispensable for in vivo and in vitro growth; however progressive Rpf deletions 
impair virulence, colony-forming ability on solid agar, and the ability to spontaneously 
recover from a dormant state (46).   
Downing and colleagues suggested a regulatory interdependence and 
communication among Rpf gene products when considering single, double, and triple 
mutants (28).  Using the Erdman type M. tuberculosis strain, Downing et al. showed that 
triple mutants of ∆rpfA ∆rpfC ∆rpfB and ∆rpfA ∆rpfC ∆rpfD showed a significant 
deficiency in resuscitation (P <0.001); with the effects of losing rpfB in combination with 
-A and -C being more catastrophic to the organism than the loss of rpfD in combination 
with –A and -C (29).  Tufariello et al. confirmed the importance of RpfB (relative to the 
other single rpf deletions) with respect to resuscitation of dormant cells with their 
Erdman type M. tuberculosis single mutant ∆Rv1009 (rpfB) (99).  This indicates that 
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there is not complete redundancy within the Rpf family of proteins, and with respect 
solely to resuscitation, there is a greater importance to the conservation of certain rpf 
sequences.   
Kana et al. created quadruple rpf mutants of M. tuberculosis that displayed no 
upregulatory compensation by expression of the remaining rpf, which refute any 
suggestion of significant crosstalk among or between rpf genes (46).  Some of the 
transcriptional regulators of rpf genes have now been recognized (72, 74).  Kana et al. 
also saw a hierarchy within the family of proteins that placed the importance of RpfB and 
-E retention greater than RpfA, -C, and -D (46).    
Initially, the Rpf protein was classified as a bacterial cytokine due to its potency 
at low concentrations (61).  More recent work has led to the classification of Rpf proteins 
as peptidoglycan hydrolases (62, 97).  Rpf proteins exhibit hydrolytic activity on the cell 
walls of both Gram-positive and Gram-negative organisms, as well as artificial lysozyme 
substrates.  However, a decrease in the ability to break down artificial peptidoglycan 
substrates indicates that the activity of Rpfs is highly specific.  When assayed with 
fluorescamine-labeled cell walls, the M. luteus Rpf exhibited a five- to six-fold decrease 
in peptidoglycan hydrolysis when compared to that of lysozyme (62).  When assayed 
with 4-methylumbelliferyl-ß-D-N-N′-N′′-triacetylchitotriose (MUF tri-NAG), the activity 
of the M. luteus Rpf diminished an additional 45 fold comparatively (62).  Recent 
structural modeling has shown that conserved regions of Rpf proteins share structural 
homology with that of lysozyme and a family of lytic transglycosylases (20, 21, 62).  Rpf 
proteins could play unique roles in the reorganization of peptidoglycan, cleavage of the 
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septum, transport of molecules across the cell wall, or production of signaling 
muropeptides in the resuscitation of dormant Mpt (62).   
Among all members of the Rpf family there is an invariant glutamate residue at 
position 54, that when altered, greatly diminishes the muralytic activity of the protein (62, 
97).  Two cysteine residues at the beginning and end of the 70-residue conserved Rpf 
domain may play a role in the binding of a cofactor (62), or serve as the sole disulfide 
bridge in the cleft area (20).  Other important structural components include a glycine-X-
X-glutamine turn motif, and glycan binding threonine and tryptophan residues (20).  
A recent discovery has shown that RpfB and -E also interact with Rpf-interacting 
protein A (RipA) (39, 40).  RipA is a peptidoglycan endopeptidase that co-localizes with 
RpfB at the septum of dividing cells.  RpfB is thought to cleave the ß-1,4-glycosidic 
bonds in peptidoglycan, while RipA hydrolyzes peptide cross-linkages (39, 40).  Hett et 
al. (39) showed that RipA is vital for actively growing cells, and provided further 
evidence that RpfB alone is insufficient.  They also showed that the combined effort of 
both enzymes cleaves peptidoglycan much more efficiently than does either enzyme 
individually (39); however, no trials were completed on cultures grown to a dormant 
state.  Due to the potential lethality of unregulated peptidoglycan hydrolases, it would not 
be striking to find more protein-protein interactions existing within the Rpf family (41).   
Interestingly, Mycobacterium leprae, which through reductive evolution has lost 
~30% of its genome and ~40% of its protein-coding genes when compared to other 
mycobacteria, has retained its genes for RpfA, -B, and -C (22, 29).  This may indicate 
that homologues in this, and other pathogenic species, are essential.    
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Expression profiling from Tufariello et al. showed that all five M. tuberculosis rpf 
mRNA transcripts were produced, and peaked at their earliest measured interval (day 4 of 
growth at OD600 = 0.125; 3.1x107 CFU/ml) (98).  From this point, expression levels 
varied throughout the time intervals of the experiment; but unlike the M. luteus Rpf, M. 
tuberculosis Rpf mRNA transcripts, as well as 23s ribosomal rRNA, were still detectable 
4 months into extended-stationary phase (98).  Their presence was also detected in an in 
vivo murine model (98).   
This brings up two interesting questions.  First, how deep into stationary phase 
must the organism be before the effects of Rpfs are exerted?  Second, why are cells in a 
4-month extended stationary phase producing Rpfs (assuming translation is occurring) 
that are not having an auto-inducing effect?  The following are suggestions to address 
these questions.  
1) The concentrations of Rpf proteins are not optimal to induce resuscitation.   
2) There are additional factors required to exit dormancy, i.e. oxygen, nutrients, 
metabolic products, declining immunity.   
3) If additional factors are required, lasting Rpf proteins could provide the means 
to a more rapid and ensured recovery when conditions improve.   
4) The Rpf mRNA transcripts are stabilized and inactivated during the onset of 
dormancy.   
5) The peptidoglycan rearranging ability of lytic transglycosylases could provide 
the means to ensuring a more rigid and durable cell wall during transitions into 
dormancy.   
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6) The combined hydrolytic and transglycolytic ability of Rpfs serve to aid the 
recycling of cell wall material during adaptation into a spheroplastic state when 
dormancy becomes extended.   
It is more likely that in considering the properties of Rpfs, including the short half 
life (in vitro) (64), recovery from dormancy comes from their expression within lag phase 
when the organism must begin alteration of the cell wall to accommodate cell division; or 
during lag and exponential phase, when it would be beneficial to signal related cells to 
exit dormancy and begin a cooperative assault against the host.  In the Tufariello et al. 
2003 study, their earliest attempts at detect Rpf transcripts were limited to early-
exponential phase (98).    
 
Cell Walls of Dormant Organisms 
 It has been shown that when entering dormancy, both Gram-positive and Gram-
negative organisms will increase the total number of peptidoglycan cross linkages by 
converting dimers to trimers, tetramers, pentamers, and higher oligomers (69, 86).  In 
addition to these changes, Enterococcus faecalis (a Gram-positive organism) will 
produce thicker and more durable cell walls, increase the amount of lipoteichoic acid, 
increase the number of penicillin-binding proteins (PBPs), and increase the amount of the 
active cell-wall bound autolysin – muramidase (69, 86, 87).  PBP1 is a high-molecular-
weight enzyme with both transglycosylase and transpeptidase activity.  PBP5 is a low-
molecular-weight enzyme that promotes the maturation of peptidoglycan.  Low-
molecular-weight PBPs have either carboxypeptidase or DD-endopeptidase activity.  
Muramidases are also required for the cleaving of peptidoglycan during cell division.  
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Eighty-five percent of Mur1 (a muramidase) is located in the cytoplasm of exponentially 
growing cells (87).  It is inactive until it becomes transported to the cell wall.  There is a 
3-fold increase in the amount of Mur1 located in the cell walls of VBNC Gram-positive 
cells (87).  Mur1 has an increased affinity for hyper-linked peptidoglycan; however, there 
is also an increase in the amount of lipoteichoic acid in the cell walls of dormant 
organisms, which inhibits the activity of autolysins (19).  Addressing mycobacterial 
peptidoglycan specifically, during entrance into stationary phase there is a significant 
reduction of 4→3 peptide bonds between m-DAP and D-Ala, and increased 
transpeptidation of 3→3 linkages between m-DAP-m-DAP (Figure 1) (4, 47, 52).    
This rearrangement may alter the conformation of peptidoglycan, such that a 
specialized enzyme may be required to break the linkages once cell division is to resume.  
It may also change the shape of released peptidoglycan fragments, which may act as 
signaling factors in two-component regulatory systems.  If acting through two-component 
regulatory systems, the resuscitation of mycobacteria may be an act of quorum sensing 
similar the quorum sensing means of Gram-positive organisms.   
It has been hypothesized by Signoretto and colleagues that the combination of 
these events will both promote greater endurance during dormancy, as well as a means to 
recovery when growth conditions improve (87).  With a redesigned cell wall, and all 
enzymes in place and waiting, the proposed transglycosylase and lysozyme properties of 
Rpf could be the missing link in the onset of recovery from a dormant state.  Upon 
reactivation, Rpf mediated carboxypeptidase cleavage and release of muropeptides, 
particularly m-DAP-terminating disaccharide tripeptides generated during the entrance 
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into dormancy, could possibly act through PknB signaling to release the organism from 
its dormant state (47). 
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Materials and Methods 
 
 
Bacterial Cultures 
Mycobacterium avium subsp. paratuberculosis (Mpt) was propagated in 
Middlebrook 7H9 broth (Becton Dickinson, Franklin Lakes, NJ) supplemented with 10% 
oleic acid-albumin-dextrose-catalase (Becton Dickinson), 0.05% Tween 80 (Becton 
Dickinson), and 2 µg Mycobactin J (Allied Monitor, Fayette, MO) (M7H9C), in sealed 
tissue culture flasks.  Mycobacterium smegmatis and E. coli cultures were propagated in 
LB broth (Becton Dickinson).  All strains containing plasmids were grown in LB broth 
supplemented with 30-50 µg/ml kanamycin sulfate (Sigma, St. Louis, MO) or 50 µg/ml 
ampicillin (Sigma), depending on the resistance encoded within the vector.   
 Dormant Mpt were prepared by inoculating 1 ml of Mpt into 10 ml M7H9C in 15 
ml serum vials.  The vials were sealed with a rubber septum, and held at 37ºC for a 
minimum of 2 years.  Before use, a viability assay was performed via flow cytometry to 
analyze the condition of the cells.  
 E. coli XL-1, E. coli (lacZΔM15), E. coli BL21(DE3), and M. smegmatis mc2155 
cultures were propagated in LB broth and held at -80ºC after an electrocompetency 
preparation as described in the appendix. 
 
Identification of Genomic rpf Sequences 
All annotated and hypothetical Rpf protein sequences were mined from the 
following mycobacterial species using the NCBI website: M. abscessus, M. ulcerans, M. 
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marinum, M. tuberculosis, M. bovis, M. avium, and M. smegmatis.  Once determined, 
pairwise alignments were created using the protein sequences of each Rpf using CLC 
Free Workbench.  A consensus sequence produced from the alignments was used to 
probe the proteome of Mpt.  Sequences that showed homology were then realigned with 
the mycobacterial Rpf proteins to analyze the placement of each critical amino acid.   
 
Polymerase Chain Reaction 
 Primers were designed to amplify the 4 rpf sequences identified in the Mpt 
genome (rpfA, rpfB, rpfC, and rpfE).  Restriction sites were added to the 5′ tails of the 
forward and reverse oligos, and additional nucleotides were added as needed for the 
purpose of cloning in frame with the hsp60 promoter, and hexahistidine tag within the 
pMV261-derived vector, pMTS088 (Minnesota State University – Mankato, culture 
collection).  Primers were ordered from Integrated DNA Technologies (Coralville, IA) 
and diluted as 50 µM stocks.  A detailed explanation of how the primers were used is 
discussed below.    
Polymerase Chain Reactions (PCR) were set up in 50 µl aliquots to contain final 
concentrations of: 1X buffer (50 mM Tris/HCl, 10 mM KCl, 5 mM (NH4)2SO4, 2 mM 
MgCl2, pH 8.3/ 25°C), 1X GC-Rich solution (Roche, Indianapolis, IN), 5% DMSO, 200 
µM dNTPs, forward and reverse primers at 1 µM each, 4 units DyNAzyme™ II DNA 
polymerase (Finnzymes, Lafayette, CO), and DNA templates varying in concentration 
from 5 ng to a whole cell lysate.  Reactions were carried out in an Eppendorf, 
Mastercycler® Gradient thermal cycler (Eppendorf, Hauppauge, NY) using a denaturing 
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temperature of 95°C for 5 minutes, a thermal gradient across 12 lanes ranging from 50°C 
to 70.5°C, and an extension temperature of 72°C over 35 cycles.   
 
Cloning 
 Primers designed to isolate hypothetical rpf sequences from the genome of Mpt 
are as follows: Rpf1F and Rpf1R (rpfA), Rpf2F and Rpf2R (rpfE), RpfB Forw10 and 
RpfB Rev10 (rpfB), RpfC/D Forw10 and RpfC/D Rev10 (rpfC).  PCR amplicons 
generated from genomic Mpt templates were TA cloned into the plasmid vector, pSC-A, 
using a Stratagene (Santa Clara, CA) StrataClone™ PCR cloning kit at a 2:1 vol./vol. 
insert:vector ratio.  The pSC-A constructs were propagated in the E. coli strain provided 
by the manufacturer.  Blue-white screening was performed using LB agar (Becton 
Dickinson) supplemented with 50 µg/ml kanamycin (Fisher, Pittsburgh, PA) and 2% 5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) (Zymo Research, Orange, CA).   
Selected transformants were screened using PCR.  
 Secondary primer sets were required to incorporate restriction tails into the rpfA 
and rpfE sequences.  These primers included Rpf1D and Rpf1BR for the amplification of 
rpfA, and Rpf2D and Rpf2DR for the amplification of rpfE.  The pMTS089 and 
pMTS090 vectors served as templates for these PCRs.  Nucleotide sequences generated 
from these reactions were TA cloned into pSC-A, and selected for as previously 
described.   
 Transformants containing the rpf insert were grown overnight at 37°C in LB broth 
supplemented with 50 µg/ml kanamycin.  Plasmids were extracted using a Zyppy™ 
Plasmid Miniprep Kit (Zymo Research), and digested eccentrically to confirm insert 
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orientation.  Inserts were removed from vectors using restriction endonucleases 
respective to sites incorporated into the primer tails, and gel purified using a 
Zymoclean™ DNA Gel Recovery Kit (Zymo Research).  Recovered inserts were then 
ligated downstream and in frame with the hsp60 promoter, and upstream and in frame 
with the hexahistidine tag in the plasmid vector pMTS088.  The pMTS088 vector is a 
modified pMV261 construct, which contains a mycobacterial cell entry (Mce) sequence 
between the flanking hsp60 promoter and hexahistidine tag.  Mce has no affect on cell 
growth, and was used as a hexahistidine-tagged mycobacterial protein control in this 
study.  The pMTS088 derived rpf constructs were propagated using E. coli XL-1 
following electroporation using a Gene Pulser Xcell™ (Bio-Rad , Hercules, CA) set to 
2,500 V, 25 µF, and 200 Ω.  Once insert screening and orientation were confirmed, 
plasmids were extracted and electroporated into electrocompetent Mycobacterium 
smegmatis mc2155 at 1250 V, 25 µF, and 800 Ω in a 2mm cuvette.   
 
Expression 
 M. smegmatis mc2155 transformants were grown at 37°C for 72-96 hours in 30 ml 
LB with 50 µg/ml kanamycin (Fisher), and harvested using centrifugation for 10 minutes 
at 10,000 x g.  Pellets were resuspended in 250 µl 1X phosphate-buffered saline (PBS) 
with 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma) and boiled for 15 minutes.  
Alternatively, cultures were harvested using centrifugation, washed twice in 1X PBS, and 
resuspended in 1 ml 1X PBS.  Cells were then pulse sonicated for 20-second intervals 
with three repetitions, and PMSF added to a final concentration of 10 mM.  The protein 
fraction of cell lysates was quantitated using the bicinchoninic acid (BCA) assay (Pierce) 
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standardized with bovine serum albumin (BSA) (Rockland, Gilbertsville, PA).  Equal 
quantities of protein from boiled lysates were sent through SDS-PAGE, and streamlined 
into western blots.  Blotting was performed with a biotin affinity-purified rabbit anti-6X 
His antibody (Rockland).   
 Plasmid vector pMTS079 (a pET28b+ derivative) was used as a second parent 
vector for the expression of rpfB.  The pMTS079 vector was digested using NcoI 
(Fermentas, Glen Burnie, MD) and PstI (Promega, Madison, WI), allowing rpfB to be 
inserted downstream and in frame with the T7 lac promoter and upstream and in frame 
with the histidine tag provided from pET28b+ (Novagen, San Diego, CA).  The new 
construct – pMTS115 – and pMTS079 were electroporated into electrocompetent E. coli 
BL21(DE3) (Novagen) using the same parameters as described for E. coli XL-1.  
Expression conditions were optimized by growing cultures at room temperature, 30°C, 
and 37°C.  Each of the cultures was induced between 0.6 and 0.8 OD590 units with 
isopropyl-1thiol-(d)-galacto-pyranoside (IPTG) (EMD Chemicals, Gibbstown, NJ) at 
final concentrations of 0.05 mM, 0.1 mM, 0.5 mM, and 1 mM.  Ten-milliliter samples 
were drawn each hour over the four-hour period and processed for the detection of his-
tagged proteins.    
 
Recombinant Protein Isolation and Purification 
Cultures were harvested by centrifugation at 10,000 x g for 10 min, washed in 20 
mM Tris-HCl pH 8.0, and spun again at 10,000 x g for 10 min.  Pellets were resuspended 
in 2 ml BugBuster® (Novagen) reagent supplemented with 1 mg/ml lysozyme (MP 
Biomedicals, Solon, OH), 25 U Benzonase® nuclease (Novagen), 1 mM PMSF, and 
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rocked at room temperature for 30 minutes.  Cell lysates were spun down at 16,000 x g 
for 10 minutes, and pellets were resuspended in 1 ml BugBuster® reagent with final 
concentrations of lysozyme and PMSF at 1 mg/ml and 1 mM respectively.  Resuspended 
pellets were sonicated on ice at 45% duty with 5.5 output control in a Branson Sonifier 
450 (Danbury, CT) for three 10 sec pulses between 30 sec breaks.   
Soluble fractions were separated from insoluble fractions by centrifugation at 
21,000 x g for 10 min.   Pellets were resuspended in 1X Ni-NTA binding buffer pH 8.0, 
solubilized with either 6 M guanidine hydrochloride (Fluka, Buchs, Switzerland) or 8 M 
urea (Sigma), and stored overnight at 4ºC.  The following day the samples were 
centrifuged at 4,000 x g for 30 minutes to separate any remaining insoluble debris.  
Solubilized fractions were sent through HisPur Ni-NTA Resin (Pierce, Rockford, IL) 
and eluted in four 500 µl fractions.  Eluted fractions were desalted using D-Salt 
Dextran Desalting Columns (Pierce) with 3mls of 10 mM Tris-HCl pH 6.8 in 500 µl 
increments.  Samples were stored at -20ºC in 10 µl aliquots.  Eluates containing peak 
protein fractions were determined photometrically at OD280.  Once the peaks were 
determined, samples were run through SDS-PAGE and western blots.  The optical 
density of the RpfB and Mce protein bands relative to the co-purifying contaminating 
bands were measured using UVP LabWorks BioImaging Software (Upland, CA).  The 
total protein concentrations in each sample were determined using the BCA assay 
standardized with BSA.     
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Experiment Assembly 
 A 2 ml aliquot of dormant Mpt was drawn from serum vials with a 3 cc syringe 
fitted with a 25-gauge needle.  Cells were centrifuged at 10,000 x g for 7 minutes and 
resuspended in 1 ml 1X PBST.  Half the volume was diluted with 1X PBST to a 
photometric reading of 30% transmission (2.0x108 CFU/ml) at OD590.  The remaining 
500 µl was centrifuged at 10,000 x g for 7 minutes, and resuspended in an equal volume 
of M7H9C required to get the density to 30% transmission.  The culture was then serially 
diluted to a final concentration of 2.0x104 CFU/ml in 10 ml M7H9C.  Alternatively, 
cultures were serially diluted to final concentrations of 2.0x106 CFU/ml in 10 ml 
M7H9C.  Prior to inoculation, a viability assay was done on the dormant Mpt cultures 
using SYTO9® and propidium iodide (Invitrogen, Eugene, OR) by way of flow 
cytometry (Millipore, Billerica, MA). 
Recombinant RpfB and Mce were tested at two different starting concentrations.  
For the first preparation, purified recombinant Mce and RpfB were diluted to total protein 
concentrations of 1 nM in volumes of, at minimum, 100 µl M7H9C.  The second 
preparations were setup identically with RpfB and Mce at final concentrations of 12.8 
nM.    
Eight doubling dilutions of Mce and RpfB were tested against dormant Mpt, each 
in 5 replicate sets per plate.  This accounted for 10 of the 12 columns of each plate.  Of 
the remaining 2 columns, 1 contained only dormant Mpt, and the other contained only 
M7H9C (Appendix Figure 1, Appendix Figure 2, Appendix Figure 3, Appendix Figure 
4).   
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 Microplate wells were covered with a transparent seal to prevent evaporation and 
contamination.  Microplates were placed in sterile plastic containers with a benzalkonium 
chloride soaked paper towel between the microplate and the bottom of the container to 
prevent desiccation and contamination.  Containers were incubated at 37ºC.  Before 
optical densities were measured, microplates were allowed to equilibrate to room 
temperature in a laminar hood, and a new seal was placed over the wells.  Optical 
densities were measured at 590 nm every 48 hours. 
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Results 
 
 
Identification of Mpt ORFs that are Homologous to rpf ORFs of Related 
Actinobacteria 
All available annotated and hypothetical Rpf protein sequences of mycobacterial 
species were aligned according to their classification as RpfA-E.  Consensus sequences 
were determined, and used to probe the proteome of Mpt.  It was confirmed that 4 
hypothetical Rpf proteins exist in Mpt.  The GenBank accession numbers for those 
hypothetical Rpf sequences are MAP_0805c, MAP_0974, MAP_1607c, and 
MAP_2273c.  Each of the hypothetical Mpt Rpf proteins was then aligned with annotated 
mycobacterial Rpf proteins to verify the approximately 70-residue consensus, the 
flanking cysteines, the catalytic glutamate, the glycine-X-X-glutamine turn motif, and the 
NAG-binding threonine and tryptophan residues that all proteins of the Rpf family share.    
The RpfA alignment is shown in figure 2.  The RpfB alignment is shown in figure 3.  The 
RpfC alignment is shown in figure 4.  The RpfE alignment is shown in figure 5.   
 
Cloning 
  Primers were first designed to isolate the rpf homologues from the genome of 
Mpt.  Restriction tags were incorporated into the 5’ tails of the primers that amplified 
rpfC and rpfB, but not rpfA or rpfE (described in table 2).  Each of the 4 rpf sequences 
was then TA cloned into pSC-A.  The names of those primers and the pSC-A derived 
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constructs that were produced using the amplicons generated from those primers are 
listed in table 3.  The pSC-A vector is described in figure 6.    
Once the rpf-pSC-A constructs were produced, a second set of primers containing 
restriction elements was designed to amplify rpfA and rpfE from pMTS089 and 
pMTS090 (described in table 2).  Primer sequences are listed in table 4.  The PCR 
amplified products were then TA cloned into pSC-A to produce the vectors pMTS099 
and pMTS100.  The construction of all 6 rpf-pSC-A plasmids was confirmed using PCR 
and restriction endonuclease digestion.   
Following BamHI and NsiI digestion of the pSC-A constructs pMTS099, 
pMTS100, pMTS110, and NcoI and NsiI digestion of pMTS109, all sequences were 
ligated into the modified pMTS088 vector (a pMV261 derivative).  The pMTS088 vector 
is described in figure 7.  DNA sequencing reactions were performed using an ABI 
Prism®.  Primers designed for the purpose of DNA sequencing are listed in table 3.  The 
sequence of each primer is listed in table 4.  DNA sequencing allowed us to analyze the 
5’ and 3’ linkages, and confirm that all inserted sequences were in frame with the 
hexahistidine tag, the heat-shock promoter of pMTS088, and the mycobacterial hsp60 
Shine-Dalgarno sequence – 5′ CGGAGGA 3′ (55, 65).  The DNA sequencing results 
were aligned with the predicted rpf constructs to verify the predicted constructs were 
assembled correctly.  All sequences were confirmed, with the exception of pMTS105 
(thought to contain rpfE), which contained a mismatched section upstream of the 3′ 
NsiI/PstI link (figure 9).  The pMTS104 sequencing results are shown in figure 8.  The 
pMTS105 sequencing results are shown in figure 9.  The pMTS112 sequencing results 
are shown in figure 10.  The pMTS113 sequencing results are shown in figure 11.  The 
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rpfB sequence was also ligated into the modified pMTS079 vector (a pET28b+ 
derivative), producing the vector pMTS115.  The presence of rpfB in pMTS115 was 
confirmed using PCR and restriction endonuclease digestion.  The pMTS079 vector is 
described in figure 12.  The pMTS115 vector is described in figure 13.  Detailed 
descriptions of each pSC-A, pMV261, and pET28b+ derived construct are given in table 
1.   
 
Expression 
 No his-tagged proteins were detected from any attempts at expression within M. 
smegmatis mc2155, including pMTS088 – the positive control (figure 14).  Previous 
attempts at expression of recombinant his-tagged mce from pMTS088 in M. smegmatis 
mc2155 have been successful (Secott, unpublished) however those results could not be 
replicated.  For this reason, the plan to express recombinant-mycobacterial proteins in a 
mycobacterial host was abandoned, and efforts were put towards the expression of rpfB 
and mce in E. coli BL21(DE3) from pET28-derived vectors.   
 Initial attempts at detecting recombinant RpfB from E. coli BL21(DE3) proved 
difficult due to the lysis of the expressing cells (figure 15).  The initial attempts were 
carried out according to the manufacturer’s instructions, inducing with 1 mM IPTG and 
harvesting after a 3 hour expression time.  Upon further investigation it was found that 
there was a considerable loss of detectable recombinant RpfB using extended expression 
times (figure 16).  Considering that RpfB has the potential to be a lethal protein due to its 
ability to break glycosidic bonds of the cells wall, the graph in figure 15 gives reason to 
believe that the Mpt rpfB ORF codes for a functional protein, and E. coli BL21(DE3) is 
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able to express it in its functional conformation.  For this reason, growth and expression 
conditions were optimized with the primary interest of recovering soluble RpfB, and 
secondarily, to produce the greatest detectable quantity (see materials and methods).   
Although it is assumed that there is an active, soluble quantity of RpfB being 
translated due to the lysis of expressing cells, detection of soluble RpfB was not 
successful (exemplified in figure 16).  The conditions that promoted the best expression 
(in terms of cellular-retained quantity) were when the cells were grown at 37ºC, induced 
with 1mM IPTG between 0.6 and 0.8 OD590 units, and harvested at 1 hour post induction 
(figure 16).  This procedure, as well as all others tried, produced recombinant his-tagged 
proteins in the form of inclusion bodies.   
 The Thermo Scientific Pierce Blue Prestained Protein MW Marker was used to 
distinguish the size of recombinant proteins in SDS-PAGE gels.  The Mce and RpfB 
proteins were expected to be 48 kDa and 42 kDa, respectively.  Recombinant Mce 
migrated at a slightly slower rate than ovalbumin (47 kDa), and RpfB migrated at a 
slightly faster rate (figure 16).   
 Protein OD280 peaks following the desalting of Ni-NTA consistently occurred 
within the first 3 ml eluted.  Quantitative differences in the Mce and RpfB protein 
purifications differed between expression trials from as much as 146 µg/ml, to as little as 
6.5 µg/ml.  Although the majority of protein that eluted from the Ni-NTA column was 
consistent with the expected molecular weight of Mce and RpfB, the actual quantity of 
recombinant protein recovered was skewed by the presence of co-purifying contaminant 
proteins (seen in figure 17 and figure 18).   Optical densitometry was used to measure the 
proportion of RpfB and Mce relative to the amount of co-purifying contaminant bands.  
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The differences in optical density ranged from as little as 35% purity to as much as 100% 
purity.   
Increasing the concentration of imidazole in the column wash buffer from 20 mM 
to 50 mM appeared to increase the purity of recombinant proteins that were recovered 
(Figure 17), without affecting the affinity of hexahistidine-fused proteins to the column 
resin.  However, this varied between experiments.  Increasing the concentration of 
imidazole in the column elution buffer from 250 mM to 500 mM resulted in a product of 
comparable quantity, and lesser purity (Figure 18).   Decreasing the pH of the binding, 
wash, and elution buffers from pH 8.0 to pH 6.3 did not have an effect on the purity of 
eluted histidine-fused proteins (data not shown).  To avoid potential problems resulting 
from protein carbamylation, all proteins that were tested for bioactivity came from 
chromatography preparations in which urea was used in concert with Ni-NTA buffers at a 
slightly alkaline pH.  There did not appear to be a difference in the quantity or purity of 
recombinant proteins when inclusion bodies were solubilized with urea compared to their 
solubilization with guanidine hydrochloride (data not shown).   
Effects of Recombinant RpfB on Dormant Mpt 
 The viability assay on dormant Mpt calculated an approximate 3.5% culture 
viability.  Results showing the growth stasis of dormant Mpt with and without the 
addition of recombinant Mce and RpfB are shown in Figure 19.  The results displayed in 
figure 19 are consistent with the optical densities of all 24 plates monitored.  Dormant 
Mpt cultures did not exceed baseline turbidity levels in any of the 24 plates monitored.   
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Table 1: Vector nomenclature and hosts. 
 
Plasmid Parent Vector 
Modified Parent 
used for Cloning 
Sequence 
Inserted 
Sequence 
Template Host 
pSC-A N/A N/A N/A N/A E. coli (StrataClone) 
pMTS089 pSC-A N/A rpfA* Mpt Genome 
E. coli 
(StrataClone) 
pMTS090 pSC-A N/A rpfE* Mpt Genome 
E. coli 
(StrataClone) 
pMTS099 pSC-A N/A rpfA pMTS089 E. coli (StrataClone) 
pMTS100 pSC-A N/A rpfE pMTS090 E. coli (StrataClone) 
pMTS109 pSC-A N/A rpfB Mpt Genome 
E. coli 
(StrataClone) 
pMTS110 pSC-A N/A rpfC Mpt Genome 
E. coli 
(StrataClone) 
pMV261 N/A N/A N/A N/A M. smegmatis mc2155 
pMTS088 pMV261 pBluescriptII SK+, pSC-A, pET28b+ mce pMTS079 M. smegmatis mc
2155 
pMTS104 pMV261 pMTS088 rpfA pMTS099 M. smegmatis mc2155 
pMTS105 pMV261 pMTS088 rpfE pMTS100 M. smegmatis mc2155 
pMTS112 pMV261 pMTS088 rpfB pMTS109 M. smegmatis mc2155 
pMTS113 pMV261 pMTS088 rpfC pMTS110 M. smegmatis mc2155 
pET28b+ N/A N/A N/A N/A E. coli BL21(DE3) 
pMTS079  pET28b+ pBluescriptII SK+, pSC-A mce 
Mpt 
Genome E. coli BL21(DE3) 
pMTS115 pET28b+ pMTS079 rpfB pMTS109 E. coli BL21(DE3) 
                                                 
* Primers used to generate the rpf amplicon were designed to anneal approximately 400 
base pairs outside of the ORF in the genome of Mpt.  The construct was then used as a 
template for directional rpf cloning.   
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Table 2: Cloning and expression detail.   
 
Plasmid Forward Restriction 
Reverse 
Restriction 
Promoter / 
Expression 
Tag 
Sequence 
Verification 
Method 
Sequence 
Confirmed 
Expression 
Detected 
pSC-A N/A N/A N/A N/A N/A N/A 
pMTS089 N/A N/A N/A RE, PCR Yes, Yes N/A 
pMTS090 N/A N/A N/A RE, PCR Yes, Yes N/A 
pMTS099 BamHI NsiI N/A RE, PCR Yes, Yes N/A 
pMTS100 BamHI NsiI N/A RE, PCR Yes, Yes N/A 
pMTS109 NcoI NsiI N/A RE, PCR Yes, Yes N/A 
pMTS110 BamHI NsiI N/A RE, PCR Yes, Yes N/A 
pMV261 N/A N/A hsp60 /    N/A N/A N/A N/A 
pMTS088 BamHI, NcoI PstI 
hsp60 / 
6XHis RE, PCR Yes, Yes No 
pMTS104 N/A N/A hsp60 / 6XHis 
RE, PCR, 
Sequenced 
Yes, Yes, 
Yes No 
pMTS105 N/A N/A hsp60 / 6XHis 
RE, PCR, 
Sequenced 
Yes, Yes, 
No* No 
pMTS112 N/A N/A hsp60 / 6XHis 
RE, PCR, 
Sequenced 
Yes, Yes, 
Yes No 
pMTS113 N/A N/A hsp60 / 6XHis 
RE, PCR, 
Sequenced 
Yes, Yes, 
Yes No 
pET28b+ N/A N/A T7 lac / 6XHis N/A N/A N/A 
pMTS079 NcoI PstI T7 lac / 6XHis RE, PCR Yes, Yes Yes 
pMTS115 N/A N/A T7 lac / 6XHis RE, PCR Yes, Yes Yes 
 
                                                 
* Sequencing showed the 3′ ligation occurred between NsiI-PstI restriction sites, however 
the sequence upstream of the linkage did not match that of the hypothetical rpfE.  See 
Figure 25 for further explanation.  
RE = Restriction Endonuclease Digestion.  
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Table 3: Primer nomenclature and antibiotic resistance markers. 
 
Plasmid Cloning Primers* 5′ Sequencing Primers* 
3′ Sequencing 
Primers* 
Antibiotic   
(50 µg/ml) 
pSC-A N/A N/A N/A Kan 
pMTS089 Rpf1F, Rpf1R N/A N/A Amp 
pMTS090 Rpf2F, Rpf2R N/A N/A Amp 
pMTS099 Rpf1D, Rpf1BR N/A N/A Kan 
pMTS100 Rpf2D, Rrf2BR N/A N/A Kan 
pMTS109 RpfB Forw10,    RpfB Rev10 N/A N/A Kan 
pMTS110 RpfC/D Forw10, RpfC/D Rev10 N/A N/A Kan 
pMV261 N/A N/A N/A Kan 
pMTS088 N/A N/A N/A Kan 
pMTS104 N/A 088 HspF Link ID,    1D HspR Link ID 
109F1, 
 MsMceHisR Kan 
pMTS105 N/A 088 Hsp Link ID,         E HspR Link ID 
109F1,  
MsMceHisR Kan 
pMTS112 N/A 088 Hsp Link ID,        B HspR Link ID 
109F1,  
MsMceHisR Kan 
pMTS113 N/A 088 Hsp Link ID,    C/D HspR Link ID 
109F1,  
MsMceHisR Kan 
pET28b+ N/A N/A N/A Kan 
pMTS079 N/A N/A N/A Kan 
pMTS115 N/A N/A N/A Kan 
 
 
                                                 
* See Table 4 for the corresponding sequences and templates of each primer.   
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Table 4: Primer nomenclature.   
 
Primer ID Amplified Sequence Template Primer Sequence 5′ →  3′ RE Tag 
Rpf1F rpfA Mpt Genome gtgacgagagaggaatacatcg  N/A 
Rpf1R rpfA Mpt Genome  tgtggaagcaccagttcttc N/A 
Rpf1D rpfA pMTS089 taatGGATCCagagaggaatacatcggcgcgtatgagtgg  BamHI 
Rpf1BR rpfA pMTS089 taatATGCATggcgctgggtgcgggctgcaccagggcg  NsiI 
Rpf2F rpfE Mpt Genome  caacgggttacggaagagta N/A 
Rpf2R rpfE Mpt Genome ggtagccccatacaagacaa N/A 
Rpf2D rpfE pMTS090 taatGGATCCtcgtgcccgacccagacggcacgtcccg  BamHI 
Rpf2BR rpfE pMTS090 gctgATGCATgccgcggcggccgcacaccgggccacgcgc   NsiI 
RpfB 
Forw10 rpfB 
Mpt 
Genome CCATGGcccgcgcgttgagtgtattgacaaa  NcoI 
RpfB Rev10 rpfB Mpt Genome ATGCATaccagctcttccgctgcaca  NsiI 
RpfC/D 
Forw10 rpfC 
Mpt 
Genome GGATCCtaacgccttgttttcgcctgccgaaatg   BamHI 
RpfC/D 
Rev10 rpfC 
Mpt 
Genome ATGCATcgggaccgccgcctggatca   NsiI 
088 HspF 
Link ID 
Sequencing 
amplicon 
All 
pMV261 
derived 
vectors 
agtggcagcgaggacaacttgag  N/A 
1D HspR 
Link ID 
rpfA 
sequencing 
amplicon 
pMTS104 gcaatcttggcgacgctgacac N/A 
B HspR 
Link ID 
rpfB 
sequencing 
amplicon 
pMTS112 gcacaccgaaaccgcgtatc  N/A 
C/D HspR 
Link ID 
rpfC 
sequencing 
amplicon 
pMTS113 tgtggccaaagcgttacctattcg  N/A 
E HspR 
Link ID 
rpfE 
sequencing 
amplicon 
pMTS105   gctgaggctgttggttgaatgc  N/A 
109F1 Sequencing amplicon 
All 
pMV261 
derived 
vectors 
gaatcacttcgcaatggccaagac   N/A 
MsMceHisR Sequencing amplicon 
All 
pMTS088 
derived 
vectors 
ataTTCGAAgccaactcagcttcctttcggg  BstBI 
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Figure 1: Proposed model of peptidoglycan alterations during the transition from 
exponential growth into stationary phase.  The diagram is a simplified reproduction of 
a model produced by Kana et al. (47).  The NA/GM polymer represents the N-acetyl or 
N-glycolyl muropeptide that mycobacteria contain (56).  The left side shows the typical 
arrangement of peptidoglycan during exponential growth.  The right side shows the 
proposed arrangement of peptidoglycan in dormant mycobacteria.   
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Figure 2: Partial pairwise alignment of the annotated and hypothetical 
mycobacterial RpfA sequences.  All sequences were identified using the NCBI website.  
Alignment was created using CLC Free Workbench.  Horizontal arrows indicate the 
flanking cysteine residues near to the beginning and end of the approximately 70-residue 
core Rpf sequence.  Vertical arrows indicate the invariant glutamate, the glycine-X-X-
glutamine turn motif, and the NAG-binding threonine and tryptophan residues that all 
members of the Rpf family share.  This alignment shows the similarities that all 
annotated and hypothetical RpfA proteins share. 
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Figure 3: Partial pairwise alignment of the annotated and hypothetical 
mycobacterial RpfB sequences.  All sequences were identified using the NCBI website.  
Alignment was created using CLC Free Workbench.  Horizontal arrows indicate the 
flanking cysteine residues near to the beginning and end of the approximately 70-residue 
core Rpf sequence.  Vertical arrows indicate the invariant glutamate, the glycine-X-X-
glutamine turn motif, and the NAG-binding threonine and tryptophan residues that all 
members of the Rpf family share.  This alignment shows the similarities that all 
annotated and hypothetical RpfB proteins share. 
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Figure 4: Pairwise alignment of the annotated and hypothetical mycobacterial RpfC 
sequences.  All sequences were identified using the NCBI website.  Alignment was 
created using CLC Free Workbench.  Horizontal arrows indicate the flanking cysteine 
residues near to the beginning and end of the approximately 70-residue core Rpf 
sequence.  Vertical arrows indicate the invariant glutamate, the glycine-X-X-glutamine 
turn motif, and the NAG-binding threonine and tryptophan residues that all members of 
the Rpf family share.  This alignment shows the similarities that all annotated and 
hypothetical RpfC proteins share. 
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Figure 5: Pairwise alignment of the annotated and hypothetical mycobacterial RpfE 
sequences.  All sequences were identified using the NCBI website.  Alignment was 
created using CLC Free Workbench.  Horizontal arrows indicate the flanking cysteine 
residues near to the beginning and end of the approximately 70-residue core Rpf 
sequence.  Vertical arrows indicate the invariant glutamate, the glycine-X-X-glutamine 
turn motif, and the NAG-binding threonine and tryptophan residues that all members of 
the Rpf family share.  This alignment shows the similarities that all annotated and 
hypothetical RpfE proteins share. 
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Figure 6: pSC-A.  Plasmid vector pSC-A was used as a parent vector for the propagation 
of rpf sequences that were amplified directly from the genome of Mpt using PCR.   
Amplified rpf sequences were TA cloned into the lacZ gene coding for α-fragment of β-
galactosidase. 
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Figure 7: pMTS088, a pMV261 derived construct.  The pMTS088 vector was 
constructed by Secott and Johnson during a previous study.  The vector was designed to 
express histidine-fused mycobacterial proteins in a mycobacterial host.  The hsp60 
promoter and the hexahistidine tag in pMTS088 flank the mce sequence, which encodes a 
mycobacterial cell entry protein.  Before the mce sequence was cloned into pMV261 it 
was shuttled through pBluescriptII SK+, pET28b+, and pSC-A.  The 3′ tail of the mce 
sequence carried with it a portion of the MCS from pBluescriptII SK+, and a portion of 
the MCS from pET28b+ containing the C-terminal hexahistidine tag.  Digesting the 
pMTS088 vector with the restriction nucleases that are shown opened the vector for rpf 
cloning.   
 
 
 
 
 
 
 
 
 
48 
A: rpfA 5ʹ′ Link in pMTS104 
 
 
 
 
B: rpfA 3′ Link in pMTS104          
 
 
 
 
 
 
Figure 8: DNA sequencing results confirming the insertion of rpfA into the former 
pMTS088 construct.  The 5′ PCR amplicon (A) was amplified from pMTS104 using 
primers 088 HspF Link ID and 1D HspR Link ID.  The 3′ PCR amplicon (B) was 
amplified from pMTS104 using primers 109F1 and MsMceHisR. DNA sequencing was 
performed in Dr. Robert Sorensen’s lab at Minnesota State University – Mankato, MN.  
The pairwise alignments was produced using CLC Free Workbench to show that the 5′ 
BamHI and 3′ NsiI/PstI ligations occurred, and the sequences up and downstream of the 
linkages matched those of the expected pMTS104 sequence.  The boxes note the location 
of the restriction sites.  Nucleotides to the left of the boxes are part of the pMTS088 
sequence.  Nucleotides to the right of the boxes are part of the rpfA sequence.   
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A: rpfE 5′ Link in pMTS105 
 
 
 
 
 
B: rpfE 3′ Link in pMTS105 
 
 
 
 
 
 
Figure 9: DNA sequencing results confirming the insertion of rpfE into the former 
pMTS088 construct did not occur.  The 5′ PCR amplicon (A) was amplified from 
pMTS104 using primers 088 HspF Link ID and E HspR Link ID.  The 3′ PCR amplicon 
(B) was amplified from pMTS105 using primers 109F1 and MsMceHisR. DNA 
sequencing was performed in Dr. Robert Sorensen’s lab at Minnesota State University – 
Mankato, MN.  The pairwise alignment was produced using CLC Free Workbench to 
show that the 5′ BamHI and 3′ NsiI/PstI ligations occurred, and the sequences up and 
downstream of the linkages matched those of the expected pMTS105 sequence.  The 
boxes note the location of the restriction sites.  Nucleotides to the left of the boxes are 
part of the pMTS088 sequence.  Nucleotides to the right of the boxes are part of the rpfA 
sequence.  Although the sequencing reaction missed the targeted BamHI site in the 5′ 
link, the sequence of the rpfE PCR amplicon shares homology with the expected 
sequence.  The rpfE 3′ link does not share homology with the expected sequence.  Further 
investigation showed that the 3′ link shared homology with the mce sequence that was 
expectedly removed from pMTS088.  
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A: rpfB 5′ Link in pMTS112 
 
 
 
B: rpfB 3′ Link in pMTS112 
 
 
 
Figure 10: DNA sequencing results confirming the insertion of rpfB into the former 
pMTS088 construct.  The 5′ PCR amplicon (A) was amplified from pMTS112 using 
primers 088 HspF Link ID and 1D HspR Link ID.  The 3′ PCR amplicon (B) was 
amplified from pMTS112 using primers 109F1 and MsMceHisR. DNA sequencing was 
performed in Dr. Robert Sorensen’s lab at Minnesota State University – Mankato, MN.  
The pairwise alignment was produced using CLC Free Workbench to show that the 5′ 
NcoI and 3′ NsiI/PstI ligations occurred, and the sequences up and downstream of the 
linkages matched those of the expected pMTS112 sequence.  The boxes note the location 
of the restriction sites.  Nucleotides to the left of the boxes are part of the pMTS088 
sequence.  Nucleotides to the right of the boxes are part of the rpfB sequence.   
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A: rpfC 5′ Link in pMTS113 
 
 
 
 
B: rpfC 3′ Link in pMTS113 
 
 
 
 
 
Figure 11: DNA sequencing results confirming the insertion of rpfC into the former 
pMTS088 construct.  The 5′ PCR amplicon (A) was amplified from pMTS113 using 
primers 088 HspF Link ID and 1D HspR Link ID.  The 3′ PCR amplicon (B) was 
amplified from pMTS113 using primers 109F1 and MsMceHisR. DNA sequencing was 
performed in Dr. Robert Sorensen’s lab at Minnesota State University – Mankato, MN.  
The pairwise alignment was produced using CLC Free Workbench to show that the 5′ 
BamHI and 3′ NsiI/PstI ligations occurred, and the sequences up and downstream of the 
linkages matched those of the expected pMTS113 sequence.  The boxes note the location 
of the restriction sites.  Nucleotides to the left of the boxes are part of the pMTS088 
sequence.  Nucleotides to the right of the boxes are part of the rpfC sequence.   
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Figure 12: pMTS079, a pET28b+ derived construct.  The pMTS079 vector was 
constructed by Secott and Johnson during a previous study.  The mce sequence encodes a 
mycobacterial cell entry protein.  The NcoI restriction site in pET28b+ and the PstI 
restriction site in the mce sequence provided the means to cloning rpfB inframe with the 
T7 lac promoter and C-terminal 6XHis of pET28b+. 
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Figure 13: pMTS115, a pET28b+ derived construct.  The pMTS115 vector was 
constructed for the expression of rpfB in an E. coli system.  The rpfB sequence was first 
removed from the pMTS109 vector using the restriction endonucleases NcoI and NsiI.  
The mce sequence was removed from pMTS079 using the restriction endonucleases 
NcoI, and the NsiI isoschizomer, PstI.  The pMTS115 vector was then constructed by 
ligating rpfB into pMTS079 at the NcoI and NsiI/PstI cohesive ends.  This placed rpfB 
inframe with the T7 lac promoter and 6XHis tag of pET28b+.   
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Figure 14: Western blot of mce and rpfB expression trials in M. smegmatis mc2155.  
M. smegmatis mc2155 cultures containing either pMV261, pMTS088, or pMTS112 were 
grown for 96 hours at 37ºC.  Cultures were processed according to the methods protocol 
for the purification of hexahistidine-fused proteins.  Lanes 1-10 are described from left to 
right: lanes 1-3, concentrated culture supernates of pMV261, pMTS088, and pMTS112, 
respectively; lanes 4-6, Soluble fractions of pMV261, pMTS088, and pMTS112 cell 
lysates, respectively; lane 7, MW marker; lanes 8-10, Insoluble fractions of pMV261, 
pMTS088, and pMTS112 cell lysates, respectively.  Bands of interest are those that are 
present in RpfB and Mce preparations, and absent in pMV261 preparations.  This is seen 
at one location, indicated by the horizontal arrow (A).  However, previous research has 
shown that recombinant Mce expressed from M. smegmatis mc2155 migrates at a rate 
equal to proteins that have a molecular weight of 50 kDa (B).  The location of the 
indicated band is >50 kDa.  Along with this, RpfB is expected to migrate faster than Mce 
due its molecular weight of 42 kDa when expressed from pMTS112.   This shows that 
there is no expression of mce or rpfB from M. smegmatis mc2155.   
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Figure 15: Growth curves of E. coli BL21(DE3) after induction with 5 different 
IPTG concentrations.   Blue lines represent cultures expressing mce from pMTS079, 
and red lines represent cultures expressing rpfB from pMTS115.  The legends are listed 
in order from highest absorbance to lowest absorbance at 7.5 hours.  Cultures were 
induced with IPTG at OD590 0.6.  Cell division stopped after 90 minutes in all 
concentrations of IPTG for cultures expressing mce.  After this time the absorbance 
decreased slowly until an optical density of approximately 0.58.  Cell division stopped at 
90 minutes in cultures expressing rpfB at IPTG concentrations of 0.05 mM and 0.1 mM.  
From this point there was a rapid decline in absorbance until it reached an optical density 
of approximately 0.44.  Cell division stopped at 60 minutes in cultures expressing rpfB at 
IPTG concentrations of 0.5 mM and 1 mM.  From this point there was a dramatic decline 
in absorbance until it reached an optical density of approximately 0.44.   This indicates 
there is lytic activity of RpfB on expressing cells.  
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Figure 16: Comparative expression of mce (Panel A) and rpfB (Panel B) from E. coli 
BL21(DE3) using 1 mM IPTG for 1 hour at 37ºC vs. induction with 0.05 mM IPTG 
over 4 hours at 37ºC.  Cultures were induced with IPTG between OD590 0.6-0.8.  Ten 
milliliters of the culture induced with 1 mM IPTG was and processed at 1 hour post 
induction.  Ten milliliters of the culture induced with 0.05 mM IPTG was drawn and 
processed each hour over 4 hours.  Fifteen microliters of the soluble lysate, and urea-
solubilized lysate was then sent through a western blot using an anti-6XHis antibody at a 
1:1000 dilution. Lane 1 is the urea-solubilized fraction of the culture induced with 1 mM 
IPTG at 1 hour post induction.  Lanes 2, 4, 7, 9 are urea-solubilized cell lysates at 1, 2, 3, 
and 4 hour intervals, respectively.  Lanes 3, 5, 8, 10 are soluble fractions of the cell 
lysates at 1, 2, 3, and 4 hour intervals, respectively.  Lane 6 is the MW Marker.  This 
shows that the recombinant proteins separate with the insoluble fraction, and the largest 
quantities of recombinant protein are produced when cells are grown at 37ºC, induced 
with 1 mM IPTG, and harvested after 1 hour of expression. 
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      Panel A                Panel B 
 
Figure 17: Increasing the concentration of imidazole in the Ni-NTA wash buffer 
decreases the amount contaminating proteins in the Ni-NTA eluates.  Expression of 
rpfB after 1 hour induction with 1 mM IPTG.  Inclusion bodies were solubilized with 8 M 
urea and sent through Ni-NTA resin.  Ten-millimolar imidazole was used in the binding 
buffer, 20 mM imidazole (Panel A) or 50 mM imidazole (Panel B) was used in the wash 
buffer, and 250 mM imidazole was used in the elution buffer.  Four 500 µl volumes of 
elution buffer were applied to the resin, collected, and 15 µl of each eluate was sent 
through a 10% acrylamide gel (lanes 2-5).  Lane 1 is the MW Marker. This shows that 
when compared to a 50 mM imidazole wash (Panel B), RpfB elutes with more 
contaminating bands 
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       Panel A            Panel B 
 
Figure 18: Increasing the concentration of imidazole in the Ni-NTA elution buffer 
increases the amount contaminating proteins in the Ni-NTA eluates.  Expression of 
rpfB after 1 hour induction with 1 mM IPTG.  Inclusion bodies were solubilized with 8 M 
urea and sent through Ni-NTA resin.  Ten-millimolar imidazole was used in the binding 
buffer, 20 mM imidazole was used in the wash buffer, and 250 mM imidazole (Panel A) 
or 500 mM imidazole (Panel B) was used in the elution buffer.  Four 500 µl volumes of 
elution buffer were applied to the resin, collected, and 15 µl of each eluate was sent 
through a 10% acrylamide gel (lanes 2-5).  Lane 1 is the MW Marker.  This shows that 
when compared to a 500 mM imidazole elution (Panel B), RpfB elutes with fewer 
contaminating bands. 
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Figure 19: Growth curves of Mpt in M7H9C with and without the addition of 
recombinant Mce and RpfB.  The 96-well plate used in this assay contained 5 replicate 
trials that tested doubling dilutions of recombinant Mce and RpfB from 500 mM to 3.91 
mM on dormant Mpt in M7H9C, 8 replicate tests on dormant Mpt in M7H9C , and 8 
replicate tests on M7H9C.  Optical densities were measured over 31 days.  Since there 
was no difference between any of the trials testing varying recombinant protein 
concentrations, all 40 wells containing Mce (5 replicates of 8 different protein 
concentrations) were treated as 40 replicates to produce 1 line.  The same was done for 
RpfB-containing wells.  This figure shows that Recombinant RpfB has no effect on the 
recovery of dormant Mpt.   
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Discussion 
 
 
Our purpose in this study was to test the ability of recombinant Mpt RpfA-E to 
promote the growth of dormant Mpt.  Our bioinformatic analysis revealed four rpf ORFs 
in the genome of Mpt, consistent with the accession numbers published by Kana et al. 
(47).  DNA sequencing revealed that the Mpt rpfA, rpfB, and rpfC sequences were 
successfully cloned into the pMV261 derived vector.  Our attempts at producing 
recombinant Mce, RpfA, RpfB, and RpfC from a modified pMV261 vector in M. 
smegmatis mc2155 were unsuccessful.  Reasons for this are unclear when considering 
that previous attempts at expressing mce from the pMV261-derived construct were 
successful.  Investigations are currently in process to determine a consistent and 
repeatable means of expressing recombinant proteins from these pMV261 derived 
constructs.  Once this is accomplished, there is a greater likelihood of recovering a 
functional Rpf product, which can be tested to resuscitate dormant Mpt. 
We examined the ability of E. coli BL21(DE3) to express two mycobacterial 
proteins (Mce and RpfB) from pET28b+ derived vectors.  We also examined the potential 
functionality of the recombinant Mce and RpfB proteins on cultures of dormant Mpt.    
Our results determined that the optimal conditions for the expression of these proteins in 
E. coli, in terms of greatest cellular-retained quantity, occur when the cultures are 
induced at OD590 0.6-0.8 with 1 mM IPTG, incubated at 37ºC, and harvested at 1 hr post 
induction.  These conditions, however, resulted in the aggregation of fusion proteins as 
inclusion bodies.  These inclusion bodies had to be solubilized with chemical denaturants 
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in order to isolate the fusion proteins from the rest of the cell lysate.  In doing so, fusion 
proteins are linearized, and the potential functionality may have been compromised.  
Some proteins are known to spontaneously refold after their removal from denaturing 
conditions (i.e. RNase and prion proteins).  In considering the possibility of that some 
spontaneous reformation occurred, total protein concentrations from desalted Ni-NTA 
eluates were tested against dormant Mpt at concentrations up to 640 times greater than 
optimal RpfB concentrations required for the resuscitation of related species.  For the 
resuscitation of related species, the optimal concentration of RpfB is approximately ~13 
pM (64).   
When testing the bioactivity of recombinant proteins, it is preferable to optimize 
the expression conditions so that the protein can be isolated from a soluble fraction.  
When E. coli is being used for the expression of a foreign gene, uncertainties in the 
quality and/or quantity of an expression product can result from (i) questionable folding 
of unique protein structures, (ii) tRNA availability and rare codon demand, (iii) mRNA 
folding and stability, (iv) translational efficiency, (v) protease activity in E. coli, (vi) 
potential lethality of the recombinant expression product (54), (vii) a Met, His, or Glu 
residue being called for at the +2 location of the mRNA transcript (5), (viii) and negative 
repeating nucleic acid elements.  These variables, as well as the rate of recombinant 
protein expression and recognizable signal cleavage sites can play a role in the 
production and solubility of recombinant proteins.  A number of commercially available 
E. coli strains have been developed to overcome some of these obstacles, and a number 
of molecular techniques can be used to alter the rare codon demand of foreign sequences.   
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The following characteristics of the mce and rpfB sequences used in this 
experiment may make them less suitable for expression in E. coli: (i) use of the rare E. 
coli codons AGG, AGA, CGA, CGG (all of which code for arginine), and CCC (coding 
for proline) (11), (ii) codon adaption indices (CAI) of 0.72 and 0.74, respectively, (iii) 
rare codon frequency distributions (CFD) of 8% and 6%, respectively, (iv) and nucleic 
acid sequences containing 18 and 26 negative repeating elements (NRE), respectively 
(CAI, CFD, and NRE values were calculated using the algorithm from 
www.genscript.com/cgi-bin/tools/rare_codon_analysis).  E. coli BL21(DE3) was able to 
overcome these obstacles; however, we were unable to obtain a soluble product.  It is 
worth noting that, although a pause in translation due to the lack of appropriate tRNA can 
cause premature termination, significant reductions in total soluble protein concentrations 
have been observed in systems where codon bias was adjusted (75). 
Previous studies that attempted the expression of Rpf proteins in E. coli have 
produced mixed results.  The Zhu et al. study was successful in developing a functional 
Rpf protein in E. coli (117).  Tufariello and colleagues were unsuccessful in inducing a 
resuscitative response in dormant M. tuberculosis cultures using recombinant Rpf 
proteins expressed from E. coli (98).  Mukamolova and colleagues had difficulty 
expressing a soluble and functional M. luteus rpf from pET19b using E. coli (62).  They 
were successful in using E. coli to produce a recombinant M. luteus Rpf from the 
pBAD/gIIIb vector (62).  However they were unable to test the activity of the 
recombinant M. luteus Rpf due the high level of endogenous Rpf activity in expressing 
cells, which resulted in cell lysis during expression (62).  In this study, expression of rpfB 
in E. coli from the pET28b+ vector was complicated by the incorporation of recombinant 
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RpfB into inclusion bodies and aggregation during cell lysis.  However, this study does 
suggest (i) the Mpt putative rpfB ORF codes for a functional Rpf, (ii) the Mpt rpfB was 
successfully cloned into the pET28b+ derivative, and (iii) E. coli BL21(DE3) were able 
to fold the protein properly.  The fact that inclusion bodies were our source of Rpf 
purification suggests additional possibilities: (i) there are two forms of RpfB being 
produced – one of which is functional, and one of which is aggregated; (ii) during 
expression of rpfB, the initial recombinant products produced are secreted through the 
periplasm, and as the endogenous level rises with continued expression, their 
accumulation results in aggregation.  This could explain why lysis was seen in the 
expressing cells, yet inclusion bodies were still detected.   
Although fusion proteins were obtained from E. coli expression of mce and rpfB, 
the purity and quantity of those proteins following Ni-chelate chromatography was less 
than desired, and replicate expression trials frequently led to differences in the purity and 
quantity of recombinant protein.  Hexahistidine fused contaminants were not expected 
due to the fact that our cloning designs utilized restriction sites upstream of the N-
terminal hexahistidine tag in pET28b+.   
The following ideas are possible explanations for the differences seen in purity 
and quantity of recombinant proteins.  (i) More recombinant protein is released from cells 
expressing rpfB compared to cells expressing mce due to a more complete lysis caused by 
high endogenous levels of active RpfB.  (ii) The use of denaturants may expose histidine-
dense regions in other E. coli proteins that may competitively bind to the nickel resin.  
(iii) Hydrophobic interactions occurring between the chromatography resin and 
contaminating proteins may affect the purity of the histidine tagged proteins.  Results 
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may be improved if a different purification tag is used.  Some tags, such as GST, promote 
the solubility of recombinant proteins.  Others, such as the affinity tags FLAG and HPC, 
promote greater purity of recombinant proteins due to specific epitope interactions (54).   
It is difficult to say with certainty that the differences seen from adjusting 
parameters such as imidazole concentrations and pH of the chromatography buffers had a 
direct affect on the purity and quantity of recovered proteins.  This is due to the 
comparisons being made between expression trials, and not within expression trials.  The 
differences may have resulted from inconsistencies in the total amount of recombinant 
protein expressed from cell lines, or different amounts of cellular debris solubilized with 
the inclusion bodies.  The ratio of cells transcribing recombinant sequences vs. cells that 
have adapted a resistance to IPTG may change over time, negatively affecting the 
quantity of recombinant protein relative to the total protein expressed for normal cell 
operations.  It is presumed that less than 2% of the culture is unaffected by IPTG (67).  
This percentage may vary from culture to culture, and may increase over time with 
extended storage at -80ºC, culture passage, or freeze-thaw cycling.    
Recombinant RpfB and Mce were tested against dormant Mpt, despite the issues 
of absolute purity.  The analysis of the SDS-PAGE gels using optical densitometry 
helped in deciphering the quantity of hexahistidine-fused protein that was being applied 
to dormant Mpt, relative to contaminating proteins.  The concentrations of Mpt RpfB that 
were tested against dormant Mpt varied in concentration from as high as 6.4 nM to as low 
as 3.91 nM.  Again, the exact concentration of recombinant protein added could not be 
calculated due to the protein-contaminated preparations.  None of these concentrations 
induced a response from dormant Mpt cultures when dormant cultures were added at 
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concentrations of 1.0x104 CFU/well, or 1.0x106 CFU/well (calculated by 30%T at 
OD590).  Through the use of a viability assay using flow cytometry, the actual number of 
viable cells was likely 3.54x101 CFU/well and 3.54x103 CFU/well, respective the 
photometric calculations.   
To my knowledge, this study is the second attempt at resuscitating dormant Mpt 
through the use of autologous Mpt Rpfs.  The first attempt was done by Zhu and 
colleagues, who tested the potential functionality of the putative Mpt RpfA (117).  The 
optimal concentration of Mpt RpfA observed to resuscitate dormant Mpt was 100 pM in 
the Zhu study.  No other data exists on the optimal concentrations of Rpfs required to 
resuscitate dormant Mpt, and all other studies have used mycobacterial cultures that had 
been dormant for months, not years.  Considering that optimal Rpf concentrations are 
typically consistent across genera, and even families, it is unlikely that optimal Rpf 
concentrations required for the resuscitation of dormant Mpt will differ.  However, this 
will not be certain until optimal Rpf concentrations required for the resuscitation of 
dormant Mpt are determined.   
Mycobacterial cells that have been dormant for years may differ structurally from 
cells that have been dormant for months.  As previously stated, Mpt can enter a 
spheroplastic state during periods of extended dormancy.  The high energy demand 
required to maintain the mycolates of the outer cell membrane will likely not be 
supported, and with time, the acid-fast cell wall will diminish.  When this occurs, the 
optimal concentrations of Rpf proteins required to resuscitate dormant cells may be much 
lower than concentrations required to recover “younger” dormant cultures due to the 
accessibility of exposed mycobacterial peptidoglycan.   
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As cells age in dormancy and take on a true spheroplastic state, the peptidoglycan 
disappears.  If Rpf proteins induce resuscitation by hydrolyzing glycosidic bonds of 
structurally modified cell walls, then no resuscitation would be seen from cells in a 
spheroplastic state.  However, Rpf induced recovery from dormancy may be possible for 
cells in a spheroplastic state if recovery is dependant on the products of Rpf substrate 
cleavage rather than direct Rpf hydrolysis of the cell wall.  Peptidoglycan fragments are 
activators of two-component regulatory systems, and the serine threonine protein kinase 
PknB is an essential growth mechanism in M. tuberculosis (33).  This kinase has also 
been hypothesized to serve a role in resuscitation – particularly through the means of 
recognizing structurally modified peptidoglycan that has been cleaved by Rpf proteins 
(47).   Since PknB is essential for growth, it is possible that PknB is maintained 
throughout dormancy.   
Other protein-protein interactions may exist for the proper function of RpfB on 
dormant Mpt.  RipA, for example, has been shown to co-localize with RpfB at the septum 
of dividing cells (39, 40).  Studies have been done to examine the effects of numerous rpf 
deletions, and results from those studies have concluded that there is a hierarchy of 
importance in the retention of certain rpf sequences when considering the ability to 
induce resuscitation.  However, no studies have shown the effects of adding combined 
Rpf proteins to dormant cultures.  Keeping in mind that (i) peptidoglycan hydrolases are 
tightly regulated by the cell,  (ii) rpfs are being found to be controlled by different 
transcriptional regulators, (iii) work with Rpf null mutants has shown diminished 
resuscitative capability with sequential deletions, (iv) expressions of all rpfs seem to 
overlap at some point during growth, and (v) redundancy among 4 conserved proteins 
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seems unlikely (especially considering that 3 homologues still exist in M. leprae), it may 
be possible that the Rpf proteins associate to form a larger complex.   
This study has produced many avenues for future research.  Now that all of the 
Mpt rpf ORFs are cloned into a mycobacterial expression vector, conditions to express 
the sequences and effects of the recombinant products can be tested against dormant Mpt.  
To make future study compare well with other Rpf studies, dormant Mpt should be tested 
within months of entering dormancy.  The choice of growth media should be better 
investigated in future trials.  Some studies show that Middlebrook 7H9 inhibits the 
recovery from dormancy (117).  This may be due to the increased metabolism resulting in 
the production of an overwhelming amount of reactive-oxygen intermediates.  If this is 
the case, the addition of Rpf proteins in combination with oxygen reducing agents may 
result in a greater number of cells recovering from dormancy.   
Antibodies could be produced to the RpfB proteins that were produced in this 
experiment.  These antibodies could then be applied to cultures of Mpt to determine if, 
and during what stages of growth RpfB is expressed in Mpt.   
Much work is yet to be done on the study of Mpt dormancy and the effects of Rpf 
proteins on dormant Mpt.   With continued investigation, it may be found that Rpf 
proteins are the key to increasing the sensitivity of diagnostic culture, and lowering the 
incidence of JD.   
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Appendix and Protocols 
 
Agarose Gel Electrophoresis 
 
Required: Agarose Electrophoresis Matrix, 1X TBE Buffer, Gel Cast, Loading Dye, 
Parafilm, Buffer Tank, Power Source, 2 mg/ml Ethidium Bromide, UV Imaging System 
 
1. Make 1% agarose gel by adding 0.3 grams of agarose electrophoresis matrix to 29.7 
ml of 1X TBE buffer. Caution! Ethidium bromide is a known carcinogen, always 
wear gloves! 
 
2. Boil the mixture in a glass bottle for 2 minutes. 
 
3. While the Solution is boiling, setup your gel cast by taping the open ends with 
masking tape so the top of the tape is level with the sides of the cast.  Insert comb in 
the top end. 
 
4. Once the solution has air-cooled to approximately 50ºC, poor it level with the sides of 
the cast, add 10 µl of 2 mg/ml ethidium bromide, and mix with the pipette tip.  An 
agarose solution that’s too hot can warp the cast.  Improper cooling methods can 
cause inconsistencies in the gel.  Ethidium bromide is photo reactive; do your best to 
shelter it from light. 
 
5. Once the gel has solidified, remove the comb carefully.  Squirt water over the area 
where comb meets gel to lubricate as it pulls out.  Removing to fast can pull the 
agarose base of the gel through the comb slot creating an open-ended well.  Remove 
the masking tape from the ends.  
 
6. Place the gel, still in the cast, into the buffer tank so the wells are nearest to the 
cathode.  Fill the buffer tank with 1X TBE buffer so that the buffer rises just over the 
top of the gel.   
 
7. Mix your sample on a square of parafilm with the loading dye to a final concentration 
of 1X.  Your final volume should not exceed 30 µl.  Carefully load your samples into 
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the wells.  If your number of samples is less the number of available wells, avoid 
using the outermost wells.  Be sure to save one lane for your ladder. 
8. Place the lid over the tank and connect the cables with concern to the cathode and 
anode.  Switch on the power supply, and run the gel at 145 V for approximately 45 
minutes, or until the bromphenol blue in the loading dye travels ¾ the distance of the 
gel.  It should migrate with bands of approximately 500 base pairs.  
 
9. Place the gel under UV light to reveal your samples. 
 
NOTE: Proper clean up is a must! Your gel, running buffer, gel cast, box, and anything 
else you have touched will contain residual ethidium bromide.   
 
 
10X TBE Buffer 
 
Tris Base 108 g 
Boric Acid 55 g 
EDTA 9.3 g 
dH2O q.s. to 1 L 
 
 
2 mg/ml Ethidium Bromide 
 
Ethidium Bromide 0.02 g 
dH2O 10 ml 
 
Prepare in a 50 ml conical tube, wrap in foil, and store at 4ºC.  Caution! Ethidium 
bromide is a known carcinogen! Take proper precautions. 
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SDS-PAGE (Laemmli Protocol) 
 
Required: Acrylamide:Bis 37.5:1, 4X Tris-SDS pH 8.8, 4X Tris-SDS pH 6.8, TEMED, 
Fresh 10% Ammonium Persulfate, 10X Tris-Glycine, 2X loading dye, Beta 
Mercaptoethanol, Coomassie Blue Solution, Destaining Solution, Glass Casting Plates, 
Casting Clamps, Buffer Tank, Power source 
 
1. Thoroughly clean glass plates with water and 70% ethanol.   
 
2. Place the glass-plate clamps on the bench surface, and insert the glass plates.  Once 
you are sure they are flush, clamp them into place.  If they are not your gel will leak 
out the bottom before it solidifies.  Clamp glass-plate assemblies into the casting box, 
being sure the bottoms of the glass plates are seated into the foam seats. 
 
3. Combine the following for a 10% separating gel: 5 ml Acrylamide:Bis 37.5:1, 3.75 
ml 4X Tris-SDS pH 8.8, 6.25 ml dH2O, 50 µl fresh ammonium persulfate, and 10 µl 
TEMED.  Mix well, and with a P1000 micropipette dispense 5 ml between the glass 
plates.  Caution! Acrylamide is a known neurotoxin!! Wear gloves! 
 
4. Once you have 5 mls between the plates, gently dispense dH2O on top of the 
acrylamide solution until the volume reaches the top of the front glass plate. When 
solidified you will see a line develop at the gel/dH2O interface.  Wait until you see 
this before proceeding. 
 
5. Combine the following to make the stacking gel: 0.65 ml Acrylamide:Bis 37.5:1, 1.25 
ml 4X SDS-Tris pH 6.8, 3.05 ml dH2O, 25 µl fresh ammonium persulfate, and 10 µl 
TEMED. Mix well. 
 
6. Discard the excess water from the separating gel.  With a P1000 micropipette, 
dispense the stacking-gel solution on top of the separating gel until it reaches 
approximately 5 mm from the top of the front glass plate.  Being sure to avoid 
trapping bubbles, insert the gel comb into the liquid stacking-gel solution.  Some may 
spill over the front – clean appropriately wearing gloves.  Be sure the comb is seated 
against the right side of the plates.  As the level drops, add stacking-gel acrylamide 
solution in 5 µl increments to the minute gap between the left side of the comb and 
the glass plate until it solidifies.  If you do not do this you will lose the outermost 
wells of your gel.   
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7. When the stacking gel has solidified, release the clamps and wash any residual liquid 
acryladmide solution from the plates.  Place the gels in the clamping frame such that 
both of the shorter glass plates face the center, and lock into place.  Place the 
clamping frame into the buffer tank. 
 
8. Make 1X Tris-Glycine buffer by adding 40 mls of 10X Tris-Glycine buffer to 360 
mls of dH2O.  Dispense all 400 mls into the center, between the two gels.  Allow the 
excess buffer to flow in into the surrounding reserve of the buffer tank. 
 
9. Dispense 300 µl of 2X loading dye into a 500 µl tube.  Add 6 µl of beta 
mercaptoethanol and mix well.  Dispense 15 µl into an appropriate number of sample 
tubes.  Add 15 µl of your sample to each respective tube, and mix.  
 
10. Boil your samples in the thermocycler for 10 minutes.  
 
11. Dispense 25 µl of your samples into the wells of the gel with a P30 micropipette.  
Avoid using the outermost wells if you don’t need them.  Be sure to save one lane for 
your ladder.  Fill any unused wells with 1X loading dye. 
 
12. Put the lid into place with concern to the cathode and anode, and run your samples at 
165 V for 60 minutes.  Be sure to check frequently, as the buffer level between the 
gels will decrease rapidly while running.  To refill it, stop the power, and with a 10 ml 
pipette draw buffer from the reserve and dispense it back into the center.   
 
13. When the cycle is complete, discard the buffer and remove the clamping frame.  
Separate the glass plates with the gel releaser.  Cut away the stacking gel, and rinse 
the gels under dH2O.   
 
14. Rock the gels overnight in a low volume of 1X coomassie solution.   
 
15. Dispose of the used coomassie solution in a hazardous waste container, and rinse the 
gels with dH2O.  Add destaining solution and rock until the solution needs to be 
changed.  Do this until the gel is fully destained.   
 
16. Observe the bands under bright illumination.   
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Separating Gel 
Final Acrylamide Concentration in Separating Gel (%) 
Stock Solutions 
(ml) 5 6 7 7.5 8 9 10 12 13 15 
30% 
Acrylamide/ 
0.8% 
Bisacrylamide 
2.5
0 
3.0
0 
3.5
0 3.75 
4.0
0 
4.5
0 
5.0
0 
6.0
0 6.50 7.50 
4X Tris-
HCl/SDS pH 8.8 
3.7
5 
3.7
5 
3.7
5 3.75 
3.7
5 
3.7
5 
3.7
5 
3.7
5 3.75 3.75 
dH2O 
8.7
5 
8.2
5 
7.7
5 7.50 
7.2
5 
6.7
5 
6.2
5 
5.2
5 4.75 3.75 
10% APS 
(Fresh) 
0.0
5 
0.0
5 
0.0
5 0.05 
0.0
5 
0.0
5 
0.0
5 
0.0
5 0.05 0.05 
TEMED 0.01 
0.0
1 
0.0
1 0.01 
0.0
1 
0.0
1 
0.0
1 
0.0
1 0.01 0.01 
Gel % 5 10 15 
Protein 
Separation 
Range (kDa) 
60-200 16-70 12-45 
 
 
30% Acrylamide/0.8% Bisacrylamide 
 
Acrylamide 30 g 
N,N'- methylenebisacrylamide 0.8 g 
dH2O q.s. to 100 ml 
 
Keep solution away from light by wrapping the bottle with foil.  Heat solution to 37ºC 
to get chemicals into solution.  Filter with 0.45 µm-membrane filter. Caution! 
Acrylamide is a neurotoxin! Take proper precautions! 
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4X Tris-HCl/SDS Seprating Gel pH 8.8 
 
Tris-HCl 91 g 
SDS 2 g 
dH2O q.s. to 500 ml 
 
Stir reagents into solution, pH to 8.8 with HCl, filter through 0.45 µm filter, store at 
4ºC 
 
 
4X Tris-HCl/SDS Stacking Gel pH 6.8 
 
Tris-HCl 6.05 g 
SDS 0.4 g 
dH2O q.s. to 100 ml 
 
Stir reagents into solution, pH to 8.8 with HCl, filter through 0.45 µm filter, store at 
4ºC 
 
 
10% Ammonium Persulfate 
 
Ammonium Persulfate 0.1 g 
dH2O 0.9 ml 
 
Always prepare this solution fresh before use.  Store at -20ºC 
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2X Sample Buffer 
 
Tris-HCl 1.52 g 
Glycerol 20 ml 
SDS 2.0 g 
Bromphenol Blue 0.001 g 
dH2O q.s. to 100 ml 
 
Stir reagents into solution, pH to 6.8 with HCl, add 20 µl ß-mercaptoethanol per ml 
sample buffer immediately before use. 
 
 
10X SDS-PAGE Running Buffer 
 
Tris Base 30.2 g 
Glycine 144 g 
SDS 10 g 
dH2O q.s. to 1000 ml 
 
 
Coomassie Blue Solution 
 
Methanol 500 ml 
Glacial Acetic Acid 300 ml 
Coomassie Blue R 0.5 g 
dH2O q.s. to 1000 ml 
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Destaining Solution 
 
Methanol 50 ml 
Glacial Acetic Acid 70 ml 
dH2O q.s. to 1000ml 
 
 
 
References 
 T.E. Secott, MnSU-Mankato.  Lab Protocol. 2003. Preparation of Reagents for 
Denaturing Sodium Dodecylsulfate-Polyacrylamide Discontinuous Gel Electrophoresis – 
Laemmli Method.  
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Western Blotting 
 
Required: SDS-PAGE Gel, Transfer Buffer, Bio-Ice Cooling Unit with frozen water, Gel-
Holder Cassettes, Gel-Transfer Cell, Buffer Tank, Nitrocellulose Paper, Filters, Foam 
Pads, Power Source, Appropriate Antibody, Diaminobenzidine Solution, Sterile 1X 
PBST + 1% BSA, 1X PBST, Tube Roller, 50 ml Conical Tubes, Cake Pan, Magnetic Stir 
Bar, Magnetic Stir Plate,  
 
1. Streamline this protocol from step 15 of SDS-PAGE protocol. 
 
2. Cut a piece of nitrocellulose paper equal in size to the area covered by the migration 
of your bands in the polyacrylamide gel.  Trim 2 Whatman filters (per blot) equal in 
size to the foam pads.   
 
3. Assemble the gel sandwich as follows: 1) place the gel-holder cassettes in the cake 
pan, black side down.  Pour approximately 400 ml transfer buffer into cake pan.  2) 
Saturate the foam pads in transfer buffer in cake pan.  Place one pad onto each black 
panel of cassettes.  3) Place one trimmed Whatman filter on top of the saturated foam 
pad.  4) Place polyacrylamide gel in the center of the wet filter.  5) Carefully lay 
down the nitrocellulose paper on top of the gel.  6) Place 2nd trimmed Whatman filter 
on top of the nitrocellulose paper.  7) Saturate 2nd foam pad in running buffer and 
place overtop wet filter.  Careful! Be sure to exclude any and all bubbles between 
any of the layers of your gel sandwich or transfer will be incomplete! Wear nitrile 
gloves during this procedure.  Latex and bare skin will leave residues that can obscure 
your results!  
 
4. Fold down the clear side of the cassette and clamp shut.  Place the cassettes into the 
gel-transfer cell with the plastic hinges down, and orientated such that the black 
cassette panels are facing the same direction as the black side of the transfer cell.  
 
5. Pour transfer buffer from the cake pan into the buffer tank, and drop in the stir bar.  
The stir bar should be able to spin in between the center notches of the cassettes.   
 
6. Place the bio-ice cooling unit (already containing frozen water) into the remaining 
gap between the buffer tank and the gel-transfer cell.  Fill the buffer tank with the 
remaining transfer buffer until it reaches a few millimeters below the top lip of the 
buffer tank.  Fluid expansion will cause overflow of buffer if filled too high.  
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7. Set the tank on the magnetic stirrer and turn on to medium speed, being sure it rotates 
unobstructed.  Secure lid to the tank, with concern to the anode and cathode, and run 
for 1 hour at 100 V.   
 
8. When the cycle completes, pour the buffer back into the original container.  It can be 
reused approximately 5 times, or until distortion of your bands is seen.  Deconstruct 
the sandwich apparatus, and place the nitrocellulose, blot-side up, into a 50 ml conical 
tube.  Pipette 10 ml of filter-sterilized 1X PBST + 1% BSA into conical tube, and 
slide nitrocellulose paper up and down until bubbles are gone.  Put tube into a roller 
at 4ºC, and rotate for 1 hour. 
 
9. Dump 1X PBST + 1% BSA, and add 5-10 ml 1X PBST + 1% BSA + 1:1000 anti-
6XHis antibody and Spin at 4ºC for 1 hour.  
 
10. Save antibody solution for future reuse, and wash nitrocellulose paper for 1 hour by 
adding 10 ml 1X PBST and spinning at 4ºC for 1 hour.  Sequential washes and buffer 
exchanges may help eliminate background noise.  
 
11. Prepare diaminobenzidine solution by combining the following: 10 ml dH2O, 60 mg 
Tris-HCL, 6 mg diaminobenzidine, and pH to 7.2 with HCl.  
Caution! Diaminobenzidine has known health hazards!  Take proper safety 
precautions!  
 
12. Once step 10 wash has completed, dump wash buffer, and add diaminobenzidine 
solution.  Add 6.6 µl 30% H2O2 to the solution and mix briefly.  Rotate by hand at 
room temperature.  Bands should develop within 15 minutes.   
 
13. Wash nitrocellulose paper with dH2O to stop the reaction and prevent over 
development of background.  Observe bands. 
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20X PBST 
 
Sodium Phosphate (monobasic) 4.4 g 
Sodium Phosphate (dibasic) 24 g 
Sodium Chloride 170 g 
Tween 20 10 ml 
dH2O q.s. to 1000 ml 
 
Dilute 5 ml 20X PBST into 95 ml dH2O to make 1X. 
 
 
1X PBST + 1% BSA 
 
1X PBST 99 ml 
BSA 1 g 
 
Mix BSA into solution, sterile filter with 0.22 µm filter.  Dispense into two 50 ml 
conical tubes, store at 4ºC.  
 
 
Diaminobenzidine Solution 
 
Tris-HCl 0.06 g 
Diaminobenzidine 0.006 g 
dH2O 10 ml 
30% Hydrogen Peroxide 6.6 µl 
 
Mix tris into solution and pH to 7.2 with HCl, then add diaminobenzidine.  Do not add 
H2O2 until immediately before use.   Caution!  Diaminobenzidine has known health 
hazards!  Take proper precautions.   
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Competent Cell Prep and Electroporation 
 
Required: Competent Cell Line, Shaking Incubator, LB Broth, SOC Broth, 10% 
Glycerol, Centrifuge Bottles, Centrifuge, Ice, -80ºC Freezer, 2 mm Cuvette, Bio-Rad 
Gene Pulser Xcell™, LB Agar, Blood Agar, Appropriate Antibiotic, 37ºC Incubator, 
Sterile Glass Pasteur Pipttes, 6 ml Culture Tubes 
 
1. Dispense 50 ml LB broth (add 0.05% tween 20 if growing M. smegmatis mc2155) into 
a 250 ml Erlenmeyer flask, and inoculate with your cell line.  Grow at 37ºC overnight 
(for E. coli XL-1, or 48 hours for M. smegmatis mc2155) in a shaking incubator at 
2,000 RPM.   
 
2. When the incubation is complete, do a purity check by streaking the culture to blood 
agar. 
 
3. Put the cultures on ice for 3 hours.  Cool the centrifuge and rotor to 4ºC during this 
time. 
 
4. Centrifuge the cultures at 10,000 x g for 10 minutes at 4ºC.  Dump supernate, and 
resuspend the pellet in 50 ml cold-sterile 10% glycerol.   
 
5. Centrifuge as before, and resuspend the pellet in 25 ml cold-sterile 10% glycerol.   
 
6. Centrifuge as before, and resuspend the pellet in 10 ml cold-sterile 10% glycerol. 
 
7. Centrifuge as before, and resuspend the pellet in 2 ml cold-sterile 10% glycerol. 
 
8. Dispense the 2 ml suspension into 50 µl aliquots, keeping all tubes and cultures on ice 
during the step.   
 
9. Store 50 µl aliquots at -80ºC.   
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Electroporation 
 
1. Thaw competent cells on ice. 
 
2. Dispense up to 5 µl of your plasmid into the thawed cells, and mix by stirring the 
pipette.  Do not pipette up and down.  
 
3. Pipette the cell/plasmid mix into a cold 2 mm electroporation cuvette.  Wipe the 
metal edges dry with a paper towel. 
 
4. Shock the cells in the Bio-Rad Gene Pulser Xcell™.  For E. coli strains use the 
following parameters: 2,500 V, 25 µF, and 200 Ω. For M. smegmatis use the 
following parameters: 1250 V, 25 µF, and 800 Ω.  If electrical arcing occurs, lower 
your DNA concentration or make new competent cells.  
 
5. Immediately following electroporation, use a glass Pasteur pipette to pipette 1 ml pre-
warmed SOC broth into the cuvette, pipette up and down to mix, and move to a 6 ml 
culture tube.  
 
6. Incubate E. coli strains for 1 hour, or M. smegmatis strains for 2 hours in a shaking 
incubator at 37ºC.  
 
7. Prepare 2 LB agars supplemented with an appropriate antibiotic.  
 
8. Pipette 100 µl of your culture to the surface of one of the prepared LB-antibiotic 
agars, and the remaining 900 µl to the other (these volumes may need to be 
optimized).   
 
9. Spread the volumes evenly across the entire surface of the agar, being sure the liquid 
is entirely absorbed into the agar before proceeding to the next step (allowing the 
agars to “dry” in the laminar-flow hood by leaving the lids off for an hour may 
expedite the process).    
 
10. Incubate E. coli cultures overnight, or M. smegmatis cultures for 48 hours at 37ºC.   
 
11. Screen colonies by PCR.  
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12. Subculture multiple colonies that screen positive in LB broth supplemented with the 
appropriate antibiotic.  Store cultures in 10% glycerol at -80ºC and -20ºC in replicate.  
 
 
10% Glycerol 
  
Glycerol 10 ml 
dH2O 90 ml 
 
Autoclave and store at 4ºC. 
 
 
LB Broth 
  
LB Broth Base 20  g 
Tween 20 (if growing M. smegmatis mc2 155) 500 µl 
dH2O 1000 ml 
 
Autoclave immediately after prepared, store at 4ºC. Add 10 g/L NaCl for Miller 
formulation. 
 
 
LB Agar 
 
LB Broth Base 20  g 
Agar-Agar 15 g 
dH2O 1000 ml 
 
Boil contents into solution.  Cool to 50ºC, and dispense into 20 ml aliquots.  
Autoclave, and store at 4ºC.  
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SOC Broth 
 
Sterile Filtered 20% Dextrose 20 ml 
1 M MgCl2 10 ml 
1 M MgSO4 10 ml 
SOB broth 960 ml 
 
1 M MgCl2 
 
MgCl2•6H2O 20.33 g 
dH2O 100 ml 
 
1 M MgSO4 
 
MgSO4•7H2O 24.65 g 
dH2O 100 ml 
 
SOB Broth 
 
Tryptone 20 g 
Sodium Chloride 0.5 g 
Yeast Extract 5 g 
dH2O q.s. to 1000 ml 
 
Autoclave SOB broth immediately after preparation.  Store SOB, SOC, and 20% 
dextrose at 4ºC 
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Recombinant Protein Expression, Cell Lysis, Ni-NTA Chromatography 
 
Expression 
 
Required: 250 ml Erlenmeyer Flasks, LB broth, 50 mg/ml Kanamycin, 500 mM IPTG, 
100 mM PMSF in 95% Ethanol, Shaking Incubator, Centrifuge Bottles, Centrifuge, 1 M 
Tris-HCl pH 8.0, 10% Glycerol, -20ºC Freezer, Spectrophotometer, Spectrophotometer 
Cuvettes, BugBuster® Reagent 
 
1. Transform E. coli BL21 (DE3) with your vector.  Once they have been screened for 
your DNA insert, grow them in a shaking incubator at 37ºC in 50 ml LB broth with 
30 µg/ml kanamycin to OD590 0.8.  Concentrate into 2 ml 10% sterile glycerol, 
dispense into 80µl aliquots, and freeze at -80ºC.  Note: expression will decrease with 
extended storage at 80ºC.  
 
2. Dispense 50 ml LB broth into a 250 ml Erlenmeyer flask.  Add 30 µl of 50 mg/ml 
kanamycin for a final concentration of 30 µg/ml.   
 
3. Add 40 µl of concentrated transformed E. coli BL21 (DE3) cells from frozen aliquots.   
 
4. Grow cells at 37ºC (shaking) to OD590 0.6-0.8. 
 
5. Induce cells with 1 mM IPTG (100 µl of 500 mM stock IPTG), and continue 
incubation for 1 hour.  
 
6. Harvest cells by centrifugation at 10,000 x g for 10 minutes.   
 
7. Resuspend cells in 10 ml 20 mM Tris-HCl pH 8.0 (200 µl 1 M Tris-HCl pH 8.0 into 
9.8 ml dH2O).  Spin as before. 
 
8. Resuspend the cells in 1 ml 1X Ni-NTA binding buffer.  Add 1 mM PMSF (10 µl/ml 
from 100 mM stock) and freeze at -20ºC overnight in a 15 ml conical tube.  Caution! 
PMSF is extremely toxic!! Lab coat, respirator, gloves, fume hood!  Note: some 
protocols state that extended storage at -20ºC can cause inclusion bodies to become 
less soluble.  
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50 mg/ml Kanamycin 
 
Kanamycin Sulfate 0.05 g 
dH2O 1 ml 
 
Store at -20ºC 
 
500 mM IPTG 
 
IPTG 0.119 g 
dH2O 1 ml 
 
Store at -20ºC 
 
 
100 mM PMSF 
 
PMSF 0.087 g 
95% Ethanol 5 ml 
 
Store at -20ºC Caution! PMSF is extremely toxic! Take proper precautions.  
 
 
1 M Tris-HCl pH 8.0 
 
Tris-HCl 121.14 g 
dH2O q.s. to 1000 ml 
 
pH to 8.0 with HCl 
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LB Broth 
 
LB Broth Base 20  g 
dH2O 1000 ml 
 
Autoclave immediately after prepared, store at 4ºC. Add 10 g/L NaCl for Miller 
formulation. 
 
 
LB Agar 
 
LB Broth Base 20  g 
Agar-Agar 15 g 
dH2O 1000 ml 
 
Boil contents into solution.  Cool to 50ºC, and dispense into 20 ml aliquots.  
Autoclave, and store at 4ºC.  
 
10% Glycerol 
 
Glycerol 10 ml 
dH2O 90 ml 
 
Autoclave and store at 4ºC. 
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Sonication 
 
 
Required: Sonifier, 100 mM PMSF, Ice, Lab coat, Respirator, Latex Gloves, Hearing 
Protection, 1.5 ml Centrifuge Tubes,  BugBuster® reagent, 1X Ni-NTA binding buffer, 
Urea, 15 ml Conical Tubes 
 
1. Thaw cells, immediately add PMSF to final concentration of 1 mM (PMSF has a half-
life of ~ 30 min in H2O). 
 
2. Pulse-sonicate cell suspension inside the fume hood, 6 times for 10 seconds with 30 
second breaks on ice.  Avoid contact between the probe tip and the tube.  If 
suspension turns to foam while sonicating, allow liquid to settle before continuing.  
 
3. Move the suspension into a 1.5 ml centrifuge tube, and spin at max speed for 10 
minutes.  Save supernate for analysis by SDS-PAGE.  
 
4. Completely resuspend pellet in 1 ml 1:10 BugBuster® reagent, vortex, and repeat 
centrifugation.   
 
5. Repeat step 13. 
 
6. Resuspend pellet in 1X Ni-NTA binding buffer.  Add an additional 1.25 mg of 
imidazole for each ml of binding buffer to account for the volume increase from the 
addition of urea in the following step.  Move suspension into a 15 ml conical tube.   
 
7. Add urea to a final concentration of 8 M (48 mg per 1 ml binding buffer).  Vortex 
thoroughly.  Note: use of urea can be problematic.  Be sure Ni-NTA buffers have a 
slightly alkaline pH to reduce chances of protein carbamylation, while maintaining an 
appropriate polyhistidine pKa for the binding of nickel ions.  
 
8. Pulse sonicate the suspension 3 times for 10 seconds between 30 second breaks ON 
ICE (heating promotes the production of isocyanic acid from urea decomposition). 
 
 
9. Centrifuge for 30 min at 6000 x g.  During centrifugation, proceed to following steps 
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Ni-NTA Chromatography 
 
Required: Novagen® Chromatography Columns, Pierce® Disposable 10 ml 
Polypropylene Column, Clamp Stand, Tube Clamps, Ni-NTA 50% Resin Slurry, 4X Ni-
NTA Bind Buffer, 4X Ni-NTA Wash Buffer, 4X Ni-NTA Elution Buffer, Denaturant 
(urea), Imidazole, 500 mM NaOH, Ultrapure Water, 15 ml Conical Tubes, 1.5 ml 
Centrifuge Tubes, 
 
1. Place clamp stand into laminar flow hood, attach clamps, and secure Novagen® 
chromatography columns.  
 
2. Pipette 1 ml of 50% Ni-NTA slurry into the chromatography column and allow resin 
to settle by gravity.  Once settled, remove end cap and allow fluid to drain.  Equate 
resin by gravity flow with 2 ml 1X Ni-NTA buffer + 8 M urea, using the same 
calculations for urea and additional imidazole.   
 
3. Send soluble fraction from step 11 through the prepared Ni-NTA resin, collect in a 15 
ml conical tube, and send eluate through the resin a second time.   
 
4. Prepare 4 ml 1X Ni-NTA wash buffer and add 1.25 mg imidazole per 1 ml binding 
buffer, 48 mg urea, and vortex.  Note: wait to add urea until you are ready to apply 
wash buffer to the column. 
 
5. Add 2 ml wash buffer to the column, allow to flow through, and repeat with 
remaining 2 ml.  Note: baseline OD280 readings may be necessary to determine when 
all contaminating proteins have eluted.  Imidazole concentration may need to be 
optimized if contaminating proteins elute downstream.  
 
6. Prepare 2 ml 1X Ni-NTA elution buffer and add an additional 17 mg imidazole.  
Immediately before use, add 96 mg urea to bring final urea concentration to 8 M, and 
vortex.  
 
7. Elute into 1.5 ml micro-centrifuge tubes as follows with the following volumes: 
elution 1) 400 µl; elution 2) 700 µl; elution 3) 500 µl; elution 4) 500 µl.  
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8. Wash Ni-NTA resin with 5 ml dH2O, cap, add an equal resin volume of 20% EtOH 
(500 µl assuming 1 ml slurry was added in step 13).  Gently pipette up and down and 
move resin slurry to a capped, Pierce® Disposable 10 ml Polypropylene Column fit 
with one polyethylene disc placed directly above the reservoir tip.  Be sure to 
assemble column such that there is already fluid in the tip, and no bubbles.  Continue 
collecting used resin from identical-protein extractions in this column for preparation 
of reuse.  
 
Eluates containing urea can be streamlined directly into SDS-PAGE from step 18.  If 
guanidine-HCl is used as a denaturant in place of urea, eluates from step 18 must be 
either dialyzed or sent through a buffer exchange system before running through SDS-
PAGE.  For exchanging buffer, see Desalting Protocol.   
 
Preparation To Reuse Resin: 
1. Allow resin to settle in Pierce® column 
2. Prepare 15 ml 500 mM NaOH 
3. Remove cap and allow fluid to flow through 
4. Add 5 ml 500 mM NaOH and allow to flow through 
5. Cap column 
6. Add 5 ml 500 mM NaOH and let sit for 30 minutes 
7. Remove cap and allow to drain 
8. Add 5 ml 500 mM NaOH and allow to flow through 
9. Wash with 10 ml dH2O 
10. Repeat step 9 
11. Add 5 ml 20% EtOH and allow to flow through 
12. Cap column, add a volume of 20% EtOH equal to that of the resin volume 
13. Store at 4ºC  
 
Note 1) Preparing the resin for reuse cannot be done in the Novagen® columns.  500 mM 
NaOH will degrade the retention disc.   
 
Note 2) This does not recharge the resin; it prepares the resin for reuse with identical 
proteins.  Recharge resin when it losses its color.  To do so, see product manual. 
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4X Ni-NTA Binding Buffer pH 8.0 
 
Sodium Phosphate (monobasic) 0.4 g 
Sodium Phosphate (dibasic) 10 g 
Sodium Chloride 14 g 
Imidazole 0.54 g 
dH2O q.s. to 200 ml 
 
pH to 8.0 with HCl 
 
 
4X Ni-NTA Wash Buffer pH 8.0 
 
Sodium Phosphate (monobasic) 0.4 g 
Sodium Phosphate (dibasic) 10 g 
Sodium Chloride 14 g 
Imidazole 1.09 g 
dH2O q.s. to 200 ml 
 
pH to 8.0 with HCl 
 
 
4X Ni-NTA Elution Buffer pH 8.0 
 
Sodium Phosphate (monobasic) 0.4 g 
Sodium Phosphate (dibasic) 10 g 
Sodium Chloride 14 g 
Imidazole 13.62 g 
dH2O q.s. to 200 ml 
 
pH to 8.0 with HCl 
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500 mM Sodium Hydroxide 
 
Sodium Hydroxide 0.3 g 
dH2O 15 ml 
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Desalting/Buffer Exchange 
 
Required: D-Salt™ Columns, 1X PBS, 10 mM Tris-HCl pH 6.8, 0.02% Sodium Azide, 
Spectrophotometer, Clamp Stand, Tube Clamps, 1.5 ml Centrifuge Tubes, 
Spectrophotometer, Quartz Cuvette, 
 
1. Remove the top column cap and clamp the desalting column into place.   
 
2. Decant the excess buffer from the surface of the top disc.  Remove the bottom cap 
and allow any remaining storage buffer to drip through. 
 
3. Slide the buffer reservoir into place at the top of the column.  Add 5 column volumes 
of 10 mM Tris-HCl pH 6.8 to the top of the column (25 ml for the 5 ml column).  
Allow to drain completely. 
 
4. Add your sample to the column and proceed to step 5 once it has stopped dripping. 
 
5. In 500 µl increments, add 10 mM Tris HCl pH 6.8 to the top of the column and 
collect the flow through in 1.5 ml centrifuge tubes.  In your initial trials, run a total 
volume of 5 ml through the column. 
 
6. Take OD280 readings from the total volume of each sample to determine which tube(s) 
contain your sample.  Note: Readings will become inaccurate as you approach 3 ml 
elution volume from the column, as the buffer you are trying to elute from will begin 
to elute with your exchange buffer.  
 
7. Confirm the presence of your protein by SDS-PAGE. 
 
8. Recharge the column by passing through 10 column volumes of 1X PBS. 
 
9. For storage, send through 5 column volumes of 0.02% sodium azide, and recap the 
top and bottom when approximately 1 ml remains above the top disc.  Store columns 
upright at 4ºC.  Caution! Sodium azide is toxic! Take proper precautions. 
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10 mM Tris-HCl pH 6.8 
 
Tris-HCl 0.242 g 
dH2O 200 ml 
 
pH to 6.8 with HCl 
 
 
20X PBS 
 
Sodium Phosphate (monobasic)  4.4 g 
Sodium Phosphate (dibasic) 24 g 
Sodium Chloride 170 g 
dH2O q.s. to 1000 ml 
 
Dilute 5 ml 20X PBS into 95 ml dH2O to make 1X.    
  
 
0.02% Sodium Azide 
 
Sodium Azide 0.04 g 
dH2O 200 ml 
 
Caution! Sodium azide is toxic! Take proper precautions. 
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Polymerase Chain Reaction 
 
This protocol was developed for amplification from high GC-containing templates. 
 
Required: 200 µl tubes, 1.5 ml Centrifuge tubes, Ultrapure Water, Primers (10 mM 
working stocks), DNA Template, 10X Buffer with MgCl2, Taq Polymerase, Roche GC-
Rich Solution, DMSO, dNTPs, Thermocycler, Ice 
 
1. UV irradiate an appropriate number of 200 µl reaction tubes and 1.5 ml master-mix 
centrifuge tubes.  
 
2. Combine the following in a 1.5 ml centrifuge tube for a 50 µl master mix: 
a. 32.5 µl ultrapure water 
b. 5 µl 10X buffer with MgCl2 
c. 1 µl 10 mM dNTPs 
d. 5 µl Roche® GC-Rich Solution 
e. 2.5 µl DMSO 
f. 1 µl 10 mM forward primer 
g. 1 µl 10 mM reverse primer 
h. 1 µl DNA template 
i. 1 µl (2 U) DyNAzyme™ II polymerase (increase to 4 U if performing PCR 
with chaotropes for the purpose of cloning) 
 
3. In a thermocycler, amplify sequence in lanes 7-9 (60.8ºC, 63.5ºC, 66.0ºC) of a 
thermal gradient ranging from 50ºC to 70.5ºC. 
 
4. Analyze your samples by agarose-gel electrophoresis.   
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DNA Ligation and Vector Construction 
 
Required: T4 DNA Ligase, 10X Buffer, 200 µl tubes, Restriction-Digested Vector and 
Insert 
 
1. UV irradiate sterile 200 µl reaction tube. 
 
2. Combine the following: 
a. 120 ng restriction-digested vector 
b. 60 ng restriction-digested insert 
c. 1 µl 10X buffer 
d. 1 µl T4 DNA ligase 
e. Q.s. to 10 µl with nuclease-free H2O 
f. Incubate overnight at 18ºC 
 
3. Transform electrocompetent or chemically competent cells, select and screen colonies 
by PCR.  
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Testing the Effects of RpfB on Dormant Mpt 
 
Required: Dormant Mycobacterium avium subsp. paratuberculosis, Thermo Scientific® 
Evolution 300 UV-Vis™, Quartz Cuvette, Microcentrifuge, 3 cc Syringe, 25 Gauge 
Syringe Needles, Middlebrook 7H9C, Sterile 1X PBST, Microcentrifuge Tubes, 
Tupperware™ Container, Sterile 96-Well Plate, Mce and RpfB Preps, 37ºC Incubator, 
Laminar Flow Hood with UV Light, 70% Ethanol, 95% Ethanol, 15 ml Conical Tube, 
Sterile Plastic Reservoirs, Thermo Scientific® Multiskan™ 96-Well Plate Reader. 
 
1. The night before you begin this setup, autoclave the following: 
a. 1X PBST 
b. 200 µl pipette tips (2-3 boxes) 
c. 1000 µl pipette tips (1 box) 
d. 10 ml glass pipettes 
e. Microcentrifuge tubes 
f. Tupperware™ container, with a paper towel in the bottom – damp with roccal, 
and the top cocked off to the side 
 
2. Allow the autoclave to cool to room temperature overnight.   
 
3. The next morning, bleach the inside of the laminar flow hood and wipe down any 
items in the hood with 70% ethanol. 
 
4. Open the autoclave and immediately slide the Tupperware™ lids into place.  Move 
all items from the autoclave into the laminar flow hood and irradiate with UV light 
for 15 minutes. 
 
 
Dormant Cell Prep 
 
1. Gently shake your dormant cells into suspension, breaking up the majority of 
flocculated cells.   
 
2. Place a drop of 95% ethanol on top of the rubber cap of the serum vial containing 
your dormant cells and allow to evaporate in the laminar hood 
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3. Assemble your syringe in the laminar hood, insert the needle through the rubber cap, 
and withdraw 2 ml (2 cc) of suspended cells. 
 
4. Dispense the 2 ml into 1 ml aliquots in two 1.5 ml microcentrifuge tubes.  Spin at 
10,000 x g for 7 minutes in a microcentrifuge. 
 
5. Aseptically dump the supernate, resuspend the cells in 500 µl 1X PBST, and combine 
the two 500 µl volumes into one tube. 
 
6. Withdraw 500 µl from the 1 ml volume, dispense into the quartz cuvette, and read in 
the % transmittance (%T) in the Evolution 300 UV-Vis™. 
 
7. Adjust the %T to approximately 30% (between 27% and 33%) by adding 1X PBST in 
50 µl increments directly to the cuvette containing the cells.  At 30%T your cell 
density will be approximately 2.0x108.  Once you have determined the volume 
necessary to dilute your cells to 30%T, fill the remaining volume of the cuvette with 
10% bleach, and wash appropriately. 
 
8. Spin down the remaining 500 µl of cells from step 10 at 10,000 x g for 7 minutes, and 
resuspend the pellet in an equal volume of M7H9C to that which it took to bring the 
cell density to 2.0x108 (30%T).   
 
9. Using two microcentrifuge tubes filled with 900 µl of M7H9C as your diluent, 
perform two 1:10 serial dilutions on your cells to bring the concentration to 2.0x106.  
Perform a 3rd dilution (1:100) by dispensing 100 µl of your cells at 2.0x106 into 10 ml 
M7H9C in a 15 ml conical tube.  This will bring your cells to a density of 2.0x104. 
 
 
Recombinant Protein Prep 
 
1. Have your protein preps ready and quantitated by BCA standardization.  
 
2. Dilute 10 µl of your protein solution (or appropriate volume depending on the 
quantitated value) in M7H9C to a final concentration of 1 nM.  You will need 
minimally, a total volume of 100 µl for 5 replicate trials.  
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Experiment Assembly 
 
 
Proceed to the following with impeccable and absolute concern to the highest allowable 
aseptic standards. 
 
1. Dispense 10 ml of M7H9C into a sterile plastic reservoir that conforms to use with a 
multichannel pipette.   
 
2. Fill the wells of a 96-well plate using the following instructions. 
 
3. Dispense 180 µl M7H9C into row A, columns 1-10. 
 
4. Dispense 100 µl M7H9C into row A, column 11 
 
5. Dispense 100 µl M7H9C into rows B-H, columns 1-11. 
 
6. Dispense 20 µl of Mce and RpfB at 1 nM into their respective wells. 
a. Mce into row A, columns 1-5 
b. RpfB into row A, columns 6-10  
 
7. Serially dilute 100 µl of row A columns 1-10 through rows B-H, columns 2-10.  
Discard 100 µl from row G. 
 
8. Empty the 10 ml of dormant Mpt at 2.0x104 into a sterile plastic reservoir. 
 
9. Add 100 µl of dormant Mpt to rows A-H, columns 1-11. 
 
10. Add 200 µl M7H9C to rows A-H, columns 12. 
 
11. Cover with cap, place into Tupperware™.  Incubate cells, tubes containing serial 
dilutions, dormant cells, and what remains of your protein dilutions to track sources 
of potential contamination. 
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Growth Monitoring 
 
1. Scan the optical density of your plates every 2 days. 
 
2. Open the Tupperware™ container in the laminar hood, and irradiate under UV light 
for 5 minutes. 
 
3. Remove the lid of the 96-well plate and place upside down to allow all condensate to 
evaporate.  Allow the temperature of the media to equilibrate to room temp. 
 
4. Aseptically seal the wells by pressing a transparent Platemax® film over the top, and 
wipe all surfaces dry.  From this point on, this seal will represent “the lid” in step 28. 
 
5. Measure the optical density of the media at 490 nm in the Multiscan™ 
spectrophotometer. 
 
6. Wipe all surfaces of the plate with 70% ethanol, place back into Tupperware™, and 
incubate. 
 
 
20X PBST 
 
Sodium Phosphate (monobasic) 4.4 g 
Sodium Phosphate (dibasic) 24 g 
Sodium Chloride 170 g 
Tween 20 10 ml 
dH2O q.s. to 1000 ml 
 
Dilute 5 ml 20X PBST into 95 ml dH2O to make 1X. 
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Middlebrook 7H9 Broth w/ 2 µg/ml Mycobactin J and 0.05% Tween 80 (M7H9C) 
 
Middlebrook 7H9 Broth Base 4.7 g 
Tween 80 0.5 ml 
Mycobactin J 4 ml 
dH2O 900 ml 
 
Mix components and autoclave.  Cool to 50ºC and aseptically add 100 ml oleic acid-
albumin-dextrose-catalase (OADC).  Alternatively, filter-sterilize the complete 
medium.  Store at 4ºC.  
 
 
 
 
Appendix Figure 1: 96-well plate layout.  M7H9C was used as the growth medium in 
all wells.  Columns A1-A10 contain dormant Mpt at 1.0x104 CFU/well in addition to the 
recombinant protein.   
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Appendix Figure 2: 96-well plate layout.  M7H9C was used as the growth medium in 
all wells.  Columns A1-A10 contain dormant Mpt at 1.0x106 CFU/well in addition to the 
recombinant protein.   
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Appendix Figure 3: 96-well plate layout.  M7H9C was used as the growth medium in 
all wells.  Columns A1-A10 contain dormant Mpt at 1.0x104 CFU/well in addition to the 
recombinant protein.   
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Appendix Figure 4: 96-well plate layout.  M7H9C was used as the growth medium in 
all wells.  Columns A1-A10 contain dormant Mpt at 1.0x106 CFU/well in addition to the 
recombinant protein.   
 
A1                       
Mce     
6.4 nM
A2                 
Mce     
6.4 nM
A3                 
Mce     
6.4 nM
A4                 
Mce     
6.4 nM
A5                 
Mce     
6.4 nM
A6
RpfB    
6.4 nM
A7     
RpfB    
6.4 nM
A8     
RpfB    
6.4 nM
A9     
RpfB    
6.4 nM
A10      
RpfB    
6.4 nM
A11 
Dormant 
Mpt @ 
1.0x106
A12    
M7H9C
B1       
Mce     
3.2 nM
B2       
Mce     
3.2 nM
B3       
Mce     
3.2 nM
B4       
Mce     
3.2 nM
B5       
Mce     
3.2 nM
B6       
RpfB    
3.2 nM
B7       
RpfB    
3.2 nM
B8       
RpfB    
3.2 nM
B9       
RpfB    
3.2 nM
B10       
RpfB    
3.2 nM
B11    
Dormant 
Mpt @ 
1.0x106
B12   
M7H9C
C1      
Mce     
1.6 nM
C2      
Mce     
1.6 nM
C3      
Mce     
1.6 nM
C4      
Mce     
1.6 nM
C5      
Mce     
1.6 nM
C6     
RpfB    
1.6 nM
C7     
RpfB    
1.6 nM
C8     
RpfB    
1.6 nM
C9     
RpfB    
1.6 nM
C10     
RpfB    
1.6 nM
C11     
Dormant 
Mpt @ 
1.0x106
C12   
M7H9C
D1      
Mce    
800 pM
D2      
Mce    
800 pM
D2      
Mce    
800 pM
D3      
Mce    
800 pM
D4      
Mce    
800 pM
D6     
RpfB   
800 pM
D7     
RpfB   
800 pM
D8     
RpfB   
800 pM
D9     
RpfB   
800 pM
D10     
RpfB   
800 pM
D11  
Dormant 
Mpt @ 
1.0x106
D12   
M7H9C
E1      
Mce    
400 pM
E2      
Mce    
400 pM
E3      
Mce    
400 pM
E4      
Mce    
400 pM
E5      
Mce    
400 pM
E6     
RpfB   
400 pM
E7     
RpfB   
400 pM
E8     
RpfB   
400 pM
E9     
RpfB   
400 pM
E10     
RpfB   
400 pM
E11    
Dormant 
Mpt @ 
1.0x106
E12   
M7H9C
F1      
Mce    
200 pM
F2      
Mce    
200 pM
F3      
Mce    
200 pM
F4      
Mce    
200 pM
F5      
Mce    
200 pM
F6       
RpfB   
200 pM
F7       
RpfB   
200 pM
F8       
RpfB   
200 pM
F9       
RpfB   
200 pM
F10       
RpfB   
200 pM
F11   
Dormant 
Mpt @ 
1.0x106
F12    
M7H9C
G1      
Mce     
100 pM
G2      
Mce     
100 pM
G3      
Mce     
100 pM
G4      
Mce     
100 pM
G5      
Mce     
100 pM
G6       
RpfB    
100 pM
G7       
RpfB    
100 pM
G8       
RpfB    
100 pM
G9       
RpfB    
100 pM
G10       
RpfB    
100 pM
G11    
Dormant 
Mpt @ 
1.0x106
G12      
M7H9C
H1       
Mce      
50 pM
H2       
Mce      
50 pM
H3       
Mce      
50 pM
H4       
Mce       
50 pM
H5       
Mce       
50 pM
H6      
RpfB     
50 pM
H7      
RpfB     
50 pM
H8      
RpfB     
50 pM
H9      
RpfB     
50 pM
H10      
RpfB     
50 pM
H11   
Dormant 
Mpt @ 
1.0x106
H12          
M7H9C
 
 
 
113 
 
 
Appendix Table 1: Mce and Rpf protein statistics.  Statistics were produced using 
CLC Free Workbench.  This figure shows the molecular characteristics of each protein.  
Numbers to the right of the amino acids represent what percentage of the protein is 
composed of that amino acid.   
 
 
 
 
 
 
 
